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The primary aim of this study was to determine the effectiveness of array-based 
technology for detecting and quantifying the presence of mosaicism. This aim was 
achieved by studying individuals having mosaicism for Down syndrome. SNP arrays 
were performed on 13 samples from individuals with mosaicism for trisomy 21, 13 
samples from individuals with normal chromosome 21complements (negative controls) 
and 5 samples from individuals with full or partial trisomy 21 (positive controls). In 
addition, BAC arrays were processed on 6 samples from individuals with mosaicism for 
trisomy 21, 3 negative controls and 1 positive control. These studies have shown that 
x 
 
 
 
array-based technology is effective for detecting mosaicism that is present in 20% or 
more cells with the results being consistent for both platforms. We also demonstrated the 
strength of array-based technology to identify previously unrecognized chromosomal 
mosaicism.  
A second aim of this study was to gain insight regarding the effect that trisomy 21 
has on telomere attrition and the frequency of chromosomal instability. This study 
provides the first reported measure of both chromosome-specific telomere lengths and the 
frequency of acquired chromosome abnormalities in trisomic cells and isogenic euploid 
cells obtained from the same individuals. A chromosome-specific telomere length assay 
was performed on lymphocytes obtained from 24 young individuals with mosaicism for 
Down syndrome. While differences in overall telomere signal intensities were observed 
between the euploid and trisomic cells within a person, strikingly similar profiles for 
chromosome-specific telomere intensities were observed between the cell types within a 
person. Analyses were also completed on lymphoblast samples obtained from 8 older 
individuals with mosaicism for Down syndrome, including 5 individuals without 
dementia and 3 individuals with dementia. In the older study subjects, a significant 
inverse correlation was observed between telomere length and the frequency of 
micronuclei, suggesting that telomeric shortening is leading to an increased frequency of 
chromosomal instability, possibly through dicentric chromosome formation. However, 
further studies of more individuals, especially additional analyses of older individuals, 
are needed. These future studies may help to identify genomic regions of interest and 
serve to inform investigators of potential candidate genes in the etiology of dementia. 
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Chapter 1 
 
Introduction 
 
Epidemiology and etiology of Down syndrome 
 
Down syndrome (OMIM90685) is the best recognized and most common 
chromosomal disorder seen in live born individuals, affecting 1/700-1/800 live births 
(Sherman et al., 2007). Down syndrome is caused by a complete or partial triplication of 
chromosome 21. This condition was first described in 1866 by John Langdon Down, but 
the etiology of Down syndrome was not known until 1959, when Lejuene demonstrated 
the presence of 3 copies of chromosome 21 in cells from individuals with Down 
syndrome (Lejuene, 1959). It is known that the extra chromosome 21 originates from 
nondisjunction during gametogenesis. Nondisjunction can occur during meiosis I (MI), 
when the homologous chromosomes pairs fail to properly complete the reduction division 
or during meiosis II (MII) when the chromatids fail to correctly separate. The use of 
DNA polymorphic markers allowed geneticists to determine the parental and meiotic 
origin of the nondisjunctional error that resulted in the presence of the extra chromosome 
21 in people having Down syndrome. In approximately 90% of individuals with Down 
syndrome, nondisjunction occurred in maternal meiosis, with the majority of these 
(~75%) arising during MI. Paternal nondisjunction and mitotic malsegregation are far 
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less prevalent, being seen in approximately 4 to 9% and 3 to 5% of cases, respectively 
(Yoon et al., 1996; Sherman et al., 2007).  
 
Progress has been made to identify associated factors that increase the risk for 
chromosome 21 nondisjunction. By far, advanced maternal age is the most significant 
risk factor (Janerich and Bracken 1986). The birth rate of infants having Down syndrome 
is dramatically increased in women older than 35 years (1.8/1000 births) and older than 
45 years (6.1/1000 births), when compared to the rates seen in 20- 24 years old women 
(0.4/1000 births) (Yoon et al., 1996). This observation, in part, can  be explained by: (1) 
an accumulation of toxic effects/environmental insults/mitochondrial mutations during 
the period of oocyte arrest; (2) a decrease in ovarian reserve/limited oocyte pool; (3) 
hormonal imbalance; (4) impaired meiotic machinery;  (5) altered meiotic 
recombination/instability during chromosome segregation; and/ or (6) accumulation of 
trisomy 21 oocytes due to preferential elimination of disomic oocytes (oocyte mosaicism 
selection model) (Sherman et al., 2007; Hultén et al., 2010).  
 
It is estimated that 95 % of individuals with Down syndrome have full or partial 
trisomy 21. Of the remaining cases, approximately 2-4% are due to translocations 
between chromosome 21 and another chromosome [e.g., t(14;21), t(21;22)] (Pangalos et 
al., 1994; Devlin and Morrison, 2004; Shin et al., 2010). Approximately three fourths of 
these unbalanced translocations are de novo mutations, with one fourth being present as a 
result of malsegregation of a familial translocation (American Academy of Pediatrics, 
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Committee on Genetics, 2001). The remaining proportion of people having Down 
syndrome (1% to 4%) has mosaicism. Mosaicism is a condition in which an individual 
has two or more genetically distinct cell lines that develop from a single zygote 
(Thompson and Thompson, 2004). In the case of mosaicism for Down syndrome, an 
individual has at least 2 populations of cells: one that has trisomy 21 (47,XX,+21 or 
47,XY,+21) and one with euploid cells (46,XX or 46,XY). 
 
Overview of Down syndrome clinical features 
The phenotype of people having Down syndrome, which is thought to result from 
the dosage imbalance of multiple genes, has been associated with more than 80 traits 
(Epstein 1986), including a small brachycephalic head, epicanthal folds, upward slanting 
palpebral fissures, Brushfield spots (speckling of iris), a small nose with a flat nasal 
bridge, small mouth, hypoplasic teeth, small ears, short neck, nuchal skin folds, single 
palmar creases, short metacarpals and phalanges, short fifth finger with clinodactyly, and 
wide spacing between the first and second toes. Besides cognitive impairment, the 
incidences of the most common clinical characteristics reported in people having Down 
syndrome are summarized in Table 1 (Committee on Genetics, American Academy of 
Pediatrics, 2001; Jones KL, 2005). Although individuals with Down syndrome are 
predisposed to develop childhood leukemia, epidemiologic studies revealed that 
individuals with Down syndrome have a lower incidence of developing solid tumors, 
especially breast cancer, when compare to the general population (Hasle et al., 2000). 
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Down syndrome has also been associated with primary gonadal deficiency, which 
contributes to their fertility reduction. Although, a number of females with Down 
syndrome have been reported to produce offspring (approximately 50% having a normal 
chromosomal complement and 50% having Down syndrome) (Sheridan et al., 1989), 
nearly all males with Down syndrome are infertile. Only a few case reports of males with 
non-mosaic Down syndrome have been reported to have offspring. Paternity studies 
completed for these cases confirmed that the men having Down syndrome were the 
biological fathers (Bobrow et al., 1992; Zuhlke et al., 1994; Pradhan et al., 2006). 
Cognitive impairment in people having Down syndrome is variable, ranging from 
mild (IQ: 50-70) to moderate (IQ: 35-50), and occasionally severe (IQ: 20-35) 
(Committee on Genetics, American Academy of Pediatrics, 2001; Jones KL, 2005; Tarek 
2005). The presence of visual and hearing impairments may further limit overall 
cognitive function, and language and psychosocial skill development. In addition, 
unrecognized thyroid dysfunction may compromise cognitive function. The development 
of seizures may also deteriorate cognitive function (Lott and Dierssen, 2010; Chen et al., 
2011). An area of particular compromise for individuals with Down syndrome appears in 
their auditory short-term memory skills, which has been conjectured to cause expressive 
language skill impairment (Chapman and Hesketh, 2001).
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Table 1: Clinical characteristics of individuals with Down syndrome  
 
 
Characteristics Percentage  
Hypotonia 80% 
Congenital heart defects, including endocardial cushion defect or atrioventricular canal 
defect, ventricular septal defect, patent ductus arteriosus, atrial septal defect, mitral valve 
prolapse with or without tricuspid valve prolapse and aortic regurgitation 
40-58% 
Hearing loss, including conductive, mixed, or sensorineural hearing loss 70-90% 
Otitis media  50-70% 
Eye diseases, including  
- Congenital cataracts 
- Acquired cataracts in adults 
- Severe refractive errors (mostly myopia) 
 
15% 
30-60% 
50% 
Obstructive  sleep apnea  50-75% 
Thyroid disease  15% 
Seizures   <9% 
Gastrointestinal tract anomalies, including  
- Duodenal atresia  
- Hirschsprung disease  
 
12% 
<1% 
Spine anomalies, including  
- Incomplete fusion of vertebral arches of lower spine  
- Atlantoaxial instability  
 
37% 
12% 
Hip dislocation 6% 
Increased risk of leukemia and leukemoid reaction <1% 
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Down syndrome: a syndrome of premature aging 
Approximately 75% of concepti with trisomy 21 die prenatally. Approximately 
85% of live born infants survive to age 1 year and 50% are expected to live longer than 
age 50 years (Tarek 2005). Congenital heart disease is the major factor that determines 
early survival. In addition, frequent infections that are presumably due to impaired 
immune responses and leukemia also contribute to high mortality (Chen et al., 2011). 
However, as a result of improvements in medical care, the survival of individuals with 
Down syndrome has markedly increased.  Life expectancy estimates for people with 
Down syndrome have increased from 9 years old in 1929 to 60 years in 2000 (Bittles and 
Glasson, 2004). Age-related disorders in individuals with Down syndrome begin earlier 
than in the general population. Several precocious aging characteristics have been 
reported in 30 to 40 year-old individuals with Down syndrome, including acquired 
cataracts, alopecia, premature graying of hair, age-related hearing loss, skin atrophy, 
hypogonadism, early onset menopause, degenerative vascular disease senile dementia 
and an increased prevalence of Alzheimer disease (Potter, 1991; reviewed in Esbensen 
2010). 
 
How people with Down syndrome age prematurely is not known. The DNA 
damage theory had been proposed to explain precocious aging in Down syndrome. This 
theory, which postulates that aging is a consequence of accumulation of unrepaired DNA 
damage, is supported by the finding of increased sensitivity to the DNA-damaging agents 
and impaired cellular reaction to DNA damage in individuals with Down syndrome 
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(Morawiec et al., 2008).  In addition, DNA damage has been found to be increased in 
individuals with Down syndrome in relation to control individuals (Maluf and Erdtmann, 
2001). An alternative explanation that has been suggested to explain the precocious aging 
of people with Down syndrome focuses on free-radical metabolism. One of the key 
enzymes involved in free-radical metabolism is superoxide dismutase (SOD-1), which is 
encoded by the SOD-1 gene on chromosome 21. This explanation is supported by the 
finding that cells from individuals with Down syndrome have a decreased ability to repair 
oxidative damage to mitochondrial DNA compared to age-matched controls (Druzhyna et 
al., 1998).  
 
 A relationship between the progression of aging and telomere length has been 
shown in chromosomally normal individuals from the general population (Wright and 
Shay, 1995; Fredrich et al., 2000; Stewart and Weinberg, 2006; Mayer, et al., 2006; Guan 
et al., 2007). A telomere is a specialized structure at the end of a chromosome that plays a 
role in ensuring chromosomal integrity. Several observations, both in vitro and in vivo, 
have shown that telomeres act as a mitotic clock; with the shortening of telomeres that 
occur with every cell division eventually causing cellular senescence and cell death 
(Herbert et al., 1999; Sherr and DePinho, 2000; Campisi, et al., 2001). Telomere 
shortening and a concomitant increase in genomic instability have also been described in 
older individuals having Down syndrome (Vaziri et al., 1993; Maluf and Erdtmann, 
2001).  
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Given that individuals with Down syndrome exhibit similar neuropathological 
features to those observed in individuals acquiring Alzheimer disease, it has been 
speculated that the neurodegenerative courses in Alzheimer disease and Down syndrome 
are closely related. Alzheimer disease is the most common form of dementia in the 
elderly. It is characterized by progressive dementia associated with several 
neuropathologic findings, including cerebral cortical atrophy and the accumulation of 
intracellular neurofibrillary tangles harboring hyperphosphorylated tau and extracellular 
β-amyloid plaques (Kimura et al., 2007). In the general population, early-onset 
Alzheimer disease symptoms usually start before age 60 to 65 years and often before age 
55 years, while the prevalence of clinical dementia/Alzheimer disease in individuals with 
Down syndrome present at an earlier age (the fourth and fifth decades of life) (Holland et 
al., 2000). However, neuropathologic characteristics consistent with Alzheimer disease 
have been observed (at autopsy) in the brains of individuals with Down syndrome as 
early as 30 years of age (Mann and Esiri 1989) and in the brains of all individuals with 
Down syndrome over the age of 40 years (Wisniewski et al., 1985). The diagnosis of 
Alzheimer disease in individuals with Down syndrome is complicated by their pre-
existing developmental delay (Brugge et al., 1994). In addition, individuals with Down 
syndrome have limitations in motor, language, communication and intellectual abilities; 
therefore the detection of subtle changes in these functioning areas requires sensitive 
assessment scales. Furthermore, individuals with Down syndrome may also have other 
health problems associated with aging (e.g., hypothyroidism and depression) that may 
mimic or mask the presence of Alzheimer disease (Bush and Beail, 2004). 
 
 
9 
 
Alzheimer disease is a genetically heterogeneous condition. Most forms of 
familial Alzheimer disease (AD1) are caused by a mutation in the gene encoding the 
amyloid precursor protein (APP; OMIM 104760) on chromosome band 21q21.2 
(http://www.ncbi.nlm.nih.gov/omim/104300). In these patients, the cerebral deposition of 
β-amyloid, the main component of amyloid plaques, has been associated with triplication 
of the APP gene (Hardy, 1992; Mann, 2004). These amyloid plaques are thought to lead 
to neuronal death and subsequently progressive signs and symptoms of Alzhemer disease. 
In addition to the APP gene, other genes on chromosome 21 that may be involved in the 
pathogenesis of Alzheimer disease include, but are not limited to, the superoxide 
dismutase (SOD-1) gene and the dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase 1A (DYRK1A). It has been speculated that oxidative stress may be relevant to 
neurodegeneration in people with Down syndrome (Percy et al., 1990), as SOD-1 is 
located on chromosome 21q22.1 and the activity of SOD-1 is elevated in their blood cells 
(De la Torre et al., 1996). SOD-1 is an enzyme that converts oxygen radicals to hydrogen 
peroxide and water. In people having Down syndrome SOD-1 activity is increased due to 
triplication of chromosome 21, with this increase being disproportionate to the activity of 
the downstream enzymes responsible for removal of hydrogen peroxide (e.g., glutathione 
peroxidase)(Brooksbank and Balazs, 1984; Dyer and Sinclair, 1998). This imbalance is 
thought to result in accumulations of hydrogen peroxide in the brain, causing neuronal 
damage which, in turn, results in the particularly rapid neurodegeneration with age that is 
similar to that seen in people having Alzheimer disease (De Haan et al., 1997). The 
DYRK1A, which is a candidate gene responsible for learning and memory deficit in 
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individuals with Down syndrome, has recently been demonstrated to be involved in the 
development of Alzheimer disease. The DYRK1A gene was found to be over expressed in 
the brains of individuals with Alzheimer disease with and without Down syndrome. 
Furthermore, an extra copy of the DYRK1 gene has been observed to lead to an increased 
expression and activity of DYRK1 kinase enzyme and has resulted in increased tau 
phosphorylation (Kimura et al., 2007; Liu et al, 2008; Wegiel et al., 2011).  
 
 Another biological factor that has been associated with the development of 
Alzheimer disease status in the general population is telomere attrition. The relationship 
between telomere shortening and Alzheimer disease has also been studied in individuals 
with Down syndrome. Jenkins et al. (2006) observed increased telomere shortening in 
adults with Down syndrome having dementia compared to age-matched individuals with 
Down syndrome who did not have dementia (Jenkins et al., 2006; Jenkins et al., 2008). 
Given that early clinical symptoms of Alzheimer disease can be very difficult to 
recognize, Jenkins et al. (2010) proposed that telomere shortening, especially for 
chromosome 21, may be used as a biomarker for early detection of Alzheimer disease in 
the Down syndrome population and could allow for benefits to be realized from early 
intervention before damage to the central nervous system occurred.  
 
The biological basis for the role of the telomere in Alzheimer disease 
development has been proposed to arise from a decreased efficiency in DNA repair 
processes, leading to the accumulation of mutations which, in turn, result in an increased 
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level of DNA damage. Aviv and Aviv (1998) proposed that erosion of the telomere leads 
to chromosomal instability. At the chromosomal level, telomeric shortening may give rise 
to acentric chromosome fragments which would not be subsequently pulled toward the 
daughter nuclei at the time of nuclear division, being left in the cytoplasm as micronuclei 
(MN)(de Lange, 2005). In addition, MN may originate from whole chromosome lagging 
(reviewed in Fenech, 2007). A strong correlation between chromosomal aberrations and 
MN formation has been shown (Jones, et al., 1994). It has also been shown that MN 
frequency increases with age (Bolognesi, et al., 1999; Bonassi, et al.,2001); toxic 
substance exposure [e.g., lead (Kasuba, et al., 2010) and arsenic (Colognato, et al., 
2007)]; and radiation exposure (Cho, et al., 2009; Banerjee et al., 2008); 
neurodegenerative diseases [e.g., Alzheimer disease (Migliore et al., 1997; Petrozzi et al., 
2002), and Parkinson disease (Petrozzi et al., 2002; Migliore et al., 2002)]; obesity and 
metabolic syndromes (Andreassi et al., 2011); and cancer (Duffaud, et al., 1997; Bonassi 
et al.,2007; Milosević-Djordjević et al., 2010). 
 
One of the methods for studying acquired chromosomal changes is through use of 
the cytokinesis-blocked micronucleus (CBMN) assay, which has been adopted by many 
laboratories. The CBMN assay, which was introduced by Fenech and Morley (1985), is a 
one of the most widely-used methods for measuring the frequency of MN. This cytome 
assay also allows for measuring other cytological structures that are indicative of 
chromosomal damage including nuclear buds (NBUD), which are thought to be a 
biomarker of eliminated amplified DNA and/or DNA repair complexes and 
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nucleoplasmic bridges (NPB), which serve as a biomarker of DNA misrepaired and/or 
telomere end-fusions. Interestingly, an increase in spontaneous MN frequency with age 
has been reported in buccal cells from individuals with Down syndrome (Thomas et al, 
2008; Ferreira et al, 2009)., but there is a paucity of reports of MN frequencies in 
lymphocytes of people having trisomy 21.  
 
Mosaicism for Down syndrome 
The reported incidence of mosaicism for trisomy 21 may represent only a subset 
of individuals having mosaicism. One of the main reasons for this bias is that 
conventional cytogenetic technologies are limited in their ability to detect mosaicism, 
especially for cases having low levels of trisomic cell lines. In addition, the phenotypic 
appearance of individuals with low level mosaicism is often subtle, leading to a lack of 
recognition of the condition based on a physical examination. Therefore, the true 
prevalence of mosaicism for Down syndrome in the general population could be 
underestimated. It has been postulated that whenever a larger number of cells are studied, 
using fluorescent in situ hybridization (FISH) methodologies, trisomy 21 mosaicism may 
be surprisingly common in the general population (Hultén et al., 2010).  
 
Trisomy 21 mosaicism can originate in two ways:  
1) Somatic origin. After fertilization involving euploid gametes, a normal zygote 
with 46 chromosomes undergoes a mitotic nondisjunctional event (or anaphase lag) 
involving a chromosome 21 to result in a cell with 3 copies of chromosome 21.  The cell 
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with three copies of chromosome 21 may continue to proliferate, giving rise to the 
trisomic cell line.  However, the reciprocal daughter cell having only one copy of the 
chromosome is more often at a selective growth disadvantage and usually will not 
continue to reproduce (Gardner & Sutherland, 1996) (Figure 1a).  
2) Meiotic origin. A meiotic error of chromosome 21 occurs during oogenesis or 
spermatogenesis which, following fertilization, results in an abnormal fertilized egg 
having 47 chromosomes (i.e., trisomic 21 zygote). A subsequent mitotic loss of the extra 
copy of chromosome 21 in one or more cells during embryogenesis, through a process 
called trisomy rescue, results in the presence of a normal cell line (Figure 1b).
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1)  
                               
 
Figure 1: Origin of trisomy 21 mosaicism. (a) Somatic origin. After fertilization of euploid gametes, a normal zygote 
with 46 chromosomes undergoes a mitotic nondisjunctional event, resulting in a cell with 3 copies of chromosome 21 
(black) and a cell with single copy of chromosome 21 (gray). The cell with one copy of chromosome 21 tends to have 
proliferative disadvantage, while the cell with 3 copies of chromosome 21 may continue to proliferate and gives rise to 
a mosaic zygote containing trisomy 21 cells and normal cell (white). (b) Meiotic origin. Following fertilization of a 
normal gamete with a gamete containing 2 copies of chromosome 21 due to a meiotic error, a trisomic zygote is 
formed. A subsequent mitotic loss of the extra copy of chromosome 21 in one or more cells occurs during 
embryogenesis, giving rise to the mosaicism.
(b) Meiotic Origin (a) Somatic Origin 
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The clinical manifestations of mosaicism for Down syndrome are highly variable, 
ranging from a phenotype comparable to that of individuals having “complete” trisomy 
21 to a nearly normal phenotype. These phenotypic differences are thought to be due to 
variable numbers of trisomic cells in different people, as well as variation from tissue to 
tissue within a person (Papavassiliou, et al. 2009). The proportion of trisomic cells 
present may be influenced by the viability of trisomic cells in the specific cell lineages. 
Mosaicism originating from a meiotic error or a mitotic error that gives rise to a trisomic 
cell line that is present during early stages of embryogenesis, such as blastulation, may 
lead to generalized mosaicism in which most tissues are affected. An error that occurs at 
a later embryonic stage, such as during gastrulation, in which the 3 major cell lineages 
(i.e., ectoderm, mesoderm and endoderm) are being established, may affect a smaller 
proportion of the cells or result in mosaicism that is confined to a certain tissue(s). The 
type of cells that are affected may also determine the phenotypic outcome. If the genetic 
information on chromosome 21 is essential for the development of the affected tissue(s), 
it could either impair the overall function of that tissue(s) or lead to a selective 
disadvantage of the trisomic cells. Herein, certain mechanisms involved in cell selection 
help prevent the abnormal trisomic cells from reproducing, which in turn minimize or 
eliminate the effects of the genetic imbalances resulting from trisomy for chromosome 
21.  
 
As noted above, individuals having a higher frequency of trisomy 21 cells tend to 
have more clinical traits than those who have lower proportions of trisomic cells 
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(Papavassiliou, et al. 2009). Correlations have also been observed between phenotypic 
findings and level of trisomy 21 cells in different tissues. For example, IQ scores have 
been negatively correlated to the proportion of trisomic buccal cells, while the presence 
of congenital heart disease has been positively correlated to the proportion of trisomic 
lymphocytes (Papavassiliou, et al. 2009). This observation could be explained by the 
underlying embryonic origin of these tissues since both buccal cells and brain cells are 
ectodermal in origin and both lymphocytes and cardiac muscle cells are derived from the 
mesoderm. Children with mosaicism for Down syndrome have been shown to have a 
significantly lower prevalence of major congenital heart disease (36.4%) than children 
with non-mosaic Down syndrome (49.3%) (Shin et al., 2010). The types of congenital 
heart disease were also found to be different between individuals with mosaicism and 
non-mosaic or “complete” trisomy 21. The atrioventricular canal defect was found to be 
more common in the individuals having “complete” trisomy 21, whereas the less severe 
anomaly, atrial septal defect, was more prevalent in mosaic individuals (Papavassiliou et 
al., 2009).  
 
Age-related changes leading to the acquisition of “mosaicism” have been 
documented in individuals having “complete” trisomy 21 (Jacob et al., 1961; Percy, et al., 
1993; Jenkins, et al., 1997). The causes of chromosome 21 loss with advanced aging are 
not clear, but could be due to: (1) an increase in abnormal cell division (e.g., higher 
frequency of mitotic nondisjunction) with increasing age leading to loss of a chromosome 
21; and (2) cell-line selection in the case of individuals having constitutional mosaicism 
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(e.g., diploid cells have proliferative advantage). Percy, et al. (1993), who observed a 
significantly increased proportion of diploid cells in older individuals having Down 
syndrome, hypothesized that the age-related loss of chromosome 21 could be related to 
the clinical expression of Alzheimer disease in these individuals, as well as individuals 
from the general population.  
 
Diagnostic tools in cytogenetics and their abilities to detect mosaicism 
While consistent constitutional mosaicism is a rare event, more recent studies 
have suggested that acquired chromosomal mosaicism may be a common event in the 
very early development of embryos (Vorsanova, 2005). Based on these new observations 
of “global” mosaicism, Iourov (2008) has speculated that residual somatic mosaicism 
may be a contributive factor affecting phenotypic expression variations in several age-
related diseases, including, but not limited to cancer (Albertson and Pinkel, 2003; 
Albertson and Pinkel, 2005).  
 
Chromosomal mosaicism can be detected by conventional Giemsa banding 
(GTG-banding) karyotype analysis, which is currently the standard diagnostic test used in 
clinical cytogenetic laboratories. This test allows for the whole genome identification of 
balanced and unbalanced numerical and structural chromosome aberrations. However, 
subtle cytogenetic aberrations may not be detected. At the level of routinely prepared 
metaphase chromosomes, which typically contain ~400-500 bands per haploid genome, 
deletions and duplications that are smaller than 5-10 Mb may not be reliably detected. 
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Deletions and duplications of 3-5 Mb can be detected by high resolution G-banding of 
prophase or early metaphase chromosomes, which contain ~800-1000 bands per haploid 
genome. However, this method, is not routinely used due to the fact that it is very labor 
intensive (Shaffer and Bejjani, 2004).  
 
In the late 1980s and early 1990s, molecular genetics techniques, in particular, 
fluorescent in situ hybridization (FISH) (Pinkel et al., 1986), were implemented in 
clinical cytogenetic laboratories. FISH is currently one of the most widely used 
diagnostic molecular cytogenetic methods and has become an essential adjuvant assay. 
FISH is based on the hybridization of complementary fluorescent-labeled probe(s) to 
target DNA sequences. It can be performed on both metaphase chromosomes and 
interphase nuclei and can allow for the detection of submicroscopic rearrangements at the 
resolution of approximately 80-200 kb (Shaffer et al., 2001). A large number of probes 
are available for different diagnosis purposes (summarized in Table 2).  
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Table 2: Variations of commonly used FISH probes 
 
 
 
 
Type of FISH probe Diagnosis purpose Reference 
Chromosome enumeration 
probes (centromeric probes)   
Detection of aneuploidy (e.g., 
trisomy 21, triomy 18 and 
trisomy 13) 
Klinger et al., 1992 
Locus-specific probes Detection of particular 
microdeletions or duplications 
(e.g., RB1 locus) 
Kallioniemi et al., 1992 
Dual color fusion probes  Detection of gene 
rearrangements in cancer (e.g. 
BCR/ABL) 
Dewald et al., 1993; Bentz et al., 1994 
Dual color break apart 
probes 
Detection of gene 
rearrangements in cancer (e.g.  
IGH/MYC) 
Einerson, et al., 2006 
Telomeric probes Detection of cryptic deletions 
and translocations in the 
telomeric regions 
NIH and Institute of Molecular 
Medicine Collaboration, 1996 
Multicolor FISH (cenM-
FISH) and/or spectral 
karyotyping (SKY)  
Characterization of a multitude 
of alterations 
Nietzel et al., 2001; Schrock et al., 1996; 
Schrock et al., 1997; Speicher et al., 
1996; Chudoba, et al., 1999 
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The use of FISH methods for scoring targeted chromosomal regions in interphase 
nuclei, in particular, allows for assessments of chromosome copy numbers from large cell 
populations, making FISH a time efficient and sensitive method. Although FISH allows 
for higher resolution for detecting small genomic abnormalities than conventional G-
banding, this approach is limited in that it lacks whole genome coverage and requires a 
priori  knowledge (e.g., distinctive dysmorphic features for genetic syndromes or 
suspected diagnosis for hematologic malignancies) to identify the test(s) that will be of 
clinical value. While 24-color FISH methods (M-FISH or SKY) provide whole genome 
coverage, these methods have limitations akin to those noted for conventional GTG-
banding, in that their ability to detect small deletions is limited. In addition, they do not 
allow for the recognition of intrachromosomal aberrations that do not result in a change 
in chromosome number or mortphology and are most effectively applied only for the 
interpretation of metaphase chromosome preparations (not interphase nuclei).  
 
 Comparative genomic hybridization (CGH), which was developed by 
Kallioniemi et al. (1992), is an alternative FISH-based methodology that uses DNA from 
the specimen being evaluated as the “probe” to determine chromosomal alterations. 
Briefly, in this method, two genomic DNA samples (test and reference) are differentially 
labeled with distinct fluorochromes and then competitively hybridized onto normal 
metaphase chromosomes. The ratio of the two fluorochromes present on the 
chromosomes are then quantified, using specialized computer software, to determine 
imbalances (gains and/or losses) in DNA sequences across the genome. However, since 
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conventional CGH is carried out on metaphase chromosomes, its resolution is limited to 
~3-10 Mb (Pinkel et al., 1998). In addition, this method cannot detect balanced 
chromosome rearrangements, such as balanced reciprocal or Robertsonian translocations 
and inversions. Recently, genomic microarrays were developed for CGH applications. 
Array CGH shares the same principles as conventional CGH, except metaphase 
chromosomes have been replaced with DNA fragments (e.g., bacterial artificial 
chromosomes [BACs], oligonucleotides and/or PCR-generated sequences) as targets for 
the hybridization (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Snijders et al., 2001; 
Pinkel and Albertson, 2001; Fiegler et al., 2003a; Fiegler et al., 2003b Veltman et al., 
2003; Vissers et al., 2003; Albertson and Pinkel, 2003).  
 
Currently there are 2 distinct types of microarray platforms: 1) single channel 
platform, in which test and reference samples are hybridized onto different matrices and 
2) two-channel platform, in which both test and reference samples are co-hybridized on 
the same matrix (i.e., array CGH). Fundamentally, they operate by the same principle. 
For array CGH platforms, DNA from test and reference samples are labeled with 
different fluorophores and then competitively hybridized to a microarray including 
hundreds to millions DNA probes that are complementary to targeted genomic regions. 
The relative fluorescence intensities of the test DNA to the reference DNA is then 
calculated, with this value typically being transformed to a log2 ratio for assessment. A 
log2 ratio represents a fold change measurement of input signals for the test and reference 
samples and therefore reflects the copy number change.  
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The resolution of array CGH is limited by the size of the target sequences, as well 
as the distance between the BACs or oligos spotted onto the array. Recently, high density 
single nucleotide polymorphism (SNP) genotyping arrays, which were originally 
designed for whole genome association studies, have gained popularity for cytogenetic 
testing. This technology relies on hybridization of one sample to an array, with the results 
of that hybridization being compared in silico to a database of standard reference DNA to 
determine the presence of imbalances. SNP arrays have the advantage that they allow for 
the detection of long contiguous stretches of homozygosity (LCSH), in addition to 
recognizing copy number gains and losses. Thus, both imbalances and LCSH, the latter 
of which may be indicative of isodisomic uniparental disomy (UPD), identity by descent, 
or loss of heterozygosity (LOH), can be detected in a single experiment.  
 
The clinical implementation of array-based technology has revolutionized 
cytogenetic diagnostic testing, being recently recommended as a first-tier assessment test 
for chromosomal imbalances (Miller et al., 2010). Array-based technologies have been 
developed for the analysis of clinically significant regions (targeted array) (Cheung et al., 
2007) and the entire genome (whole genome array) (Snijders et al., 2001; Veltman et al., 
2003; Vissers et al., 2003). The current limitations of array CGH include the inability to 
detect polyploidy and balanced chromosome rearrangements. Copy number alterations of 
unknown significance can also be problematic since significant knowledge regarding 
copy number variations (CNVs) throughout the genome and their exact roles are yet to be 
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determined. At this time, it is recommended that abnormalities or variations that are not 
recognized as variable regions in genome data bases, have reflex testing of parental 
samples to determine the clinical relevance, if any, of these findings (Manning and 
Hudgins 2007). 
 
All of the cytogenetic tools described above can be used for mosaicism detection 
(Table 3). In general, when 20, 30 or 50 cells are evaluated without detection of 
mosaicism, the lowest level of mosaicism excluded with 95% confidence is 14, 10 and 
6%, respectively (Hook, 1977). However, mosaicism that affects a small chromosomal 
region (i.e., less than 3Mb) or that is present in leukocytes other than T-cells may escape 
detection using conventional G-banding. Interphase FISH is a sensitive method for 
detecting low level mosaicism, allowing for the recognition of cell lines present in as low 
as 1% of the cell population (Dewald G, et al., 1998). However, this technology is limited 
because relatively few loci can be interrogated in a single experiment. Therefore, without 
prior knowledge of the chromosome or chromosomal region affected, mosaicism might 
be missed.  
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Table 3: Comparison of molecular cytogenetic techniques used for mosaicism detection 
 
 
Cytogenetic techniques Level of mosaicism detection 
Chromosome G-banding 6-10%
 
(Barch et al., 1997) 
FISH <1 %
 
(Dewald et al., 1998) 
Multiplex ligation-independent probe amplification 
(MLPA) 
14% (Van Opstal et al., 2009) 
Quantitative fluorescent polymerase chain reaction 
(QF-PCR) 
10% (reviewed in Hulten et al., 2003) 
Conventional CGH 16% (Lestou et al. 1999) 
Array CGH 5-20% (Ballif et al., 2006; Cheung et al., 2007; 
Conlin et al., 2010) 
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Since microarray-based technology is increasingly being used in clinical 
diagnosis, an evaluation of its sensitivity for mosaicism detection is essential. The ability 
of array-based technology to detect the presence of multiple cell populations has also 
been shown through studies of in vitro contrived cellular admixture, constitutional 
mosaicism and acquired chromosome abnormalities in cancers (Table 4). Based on their 
in vitro contrived cellular admixture studies, Ballif et al. (2006) and Scott et al (2010) 
concluded that mosaicism levels of 20% to 40% could be consistently detected using 
array technology, but that values of 10% or less could not be unequivocally distinguished 
from non-mosaic cases. Using a SNP array, Conlin et al., 2010 reported detecting 
mosaicism for complements present is a low as 5% of cells. In this study, mosaicism was 
identified from a logR ratio and B allele frequency (BAF). The latter was also suggested 
to be useful for identifying mechanisms of mosaicism occurrence (i.e., origin of 
segregation error). However, when the proportion of abnormal cells was very low (e.g., at 
5-10%), distinction between meiosis and mitosis origins were problematic. 
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Table 4: Summary of previous studies on mosaicism using array-based technologies
 
Manufacturer 
array 
 
Array 
type 
 
Specimen 
type 
 
# mosaic cases 
studied 
 
Chromosome(s) 
evaluated 
% Mosaicism (gain/loss) 
 
 
Reference 
FISH/GTG Array (% minimum detected) 
 
GenoSensor 
Array 300 
 
BAC/PAC (CGH) 
 
frozen fetal 
lung tissue 
 
1 
 
i(18q) 
 
17%(GTG),21%(FISH) 
 
NA 
 
Le Caignec et al., 
2005 
 
In house 
 
BAC (CGH) 
 
PB 
 
1 
 
monosomy 7 
 
8% 
 
5% 
 
Manten et al., 2006 
 
Signature Chip 
 
BAC (CGH) 
 
PB 
 
18a 
5b 
 
varya 
trisomy21b 
 
10-50%(uncultured cells) 
3-77% (cultured cells) 
10-50% (artificial) 
 
10% (subtle) 
20% (clear) 
 
Ballif et al., 2006 
 
In house 
targeted 
 
BAC (CGH) 
 
PB 
 
12 
 
vary 
 
1.5-31%(uncultured cells) 
2-33%(cultured cells) 
 
7.0% 
 
Cheung et al., 2007 
 
44k Agilent 
 
Oligo (CGH) 
 
PB 
 
8 
 
trisomy 13, 
trisomy 21 
 
10.3-77.1%(QF-PCR) 
 
10-12.3% 
 
Hoang et al., 2007 
 
In house 
targeted 
 
BAC (CGH) 
 
PB 
 
5 
 
trisomy 14 
 
9.5-42% (uncultured cells) 
2-15% (cultured cells) 
 
12.4% 
 
Shinawi et al., 2008 
 
GeneChip 
Mapping 250K 
Nsp Array 
 
SNP 
 
 
? PB or BM 
 
3 
 
trisomy 21 
 
25-50% 
 
NA 
 
 
Gondek et al, 2008 
 
In house 
 
BAC (CGH) 
 
PB 
 
48 
 
vary 
 
NA 
 
10% 
 
Neill et al., 2010 
 
105K Agilent 
 
Oligo (CGH) 
 
PB 
 
48 a 
4 b 
 
vary a 
trisomy 21b 
 
10-30% b 
 
21% a 
10%-20% (subtle) b 
30% (clear) b 
 
Neill et al., 2010 
 
Affymetrix 50K 
Xba Array 
 
SNP 
 
 
fibroblast 
 
6 
 
trisomy 8 
 
0-100% 
 
10% (subtle) 
20% (clear) 
 
Cross et al., 2007 
 
Affymetrix 6.0 
Array 
 
SNP 
 
PB 
 
1 
 
trisomy 21 
 
8-13% 
 
NA 
 
Leon et al., 2010 
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Table 4: Summary of previous studies on mosaicism using array-based technologies (continued) 
 
 
Manufacturer 
array 
 
Array 
type 
 
Specimen 
type 
 
# mosaic cases 
studied 
 
Chromosome(s) 
evaluated 
% Mosaicism (gain/loss) detected 
 
 
Reference 
FISH/GTG Array 
 
44K Agilent 
 
Oligo (CGH) 
 
PB, POC, 
CV 
 
7 a 
28 b 
 
vary a 
[trisomy 21, 
monosomy X, 
dup(3), del(15)] b 
 
17-94% a 
0-100%b 
 
10%  whole chromosome 
20-30%  segmental aneuploidy 
 
Scott et al., 2010 
 
Illumina  
HumanHap550 
Bead Chip (V3) 
 
SNP 
 
PB, skin 
 
21 
 
vary 
 
2-100% 
 
5% 
 
Conlin et al., 2010 
 
Illumina 
Quad610 
genotyping 
Bead Chip 
 
SNP 
 
UC 
 
1 
 
t(5;12) [del(5) 
and dup (12)] 
 
87% (AF), 13-43% 
(postmortem tissues, various 
organs) 
 
20% (UC) 
 
Veenma et al., 2010 
 
Illumina 
HumanHap 
1M Bead Chip 
 
SNP 
 
PB 
 
34 
 
Vary 
 
NA 
 
10% (UPD), 18% (del), 23% 
(dup and/or trisomy) 
 
Rodríguez-Santiago 
et al., 2010 
 
244K Agilent 
 
Oligo (CGH) 
 
PB, BM 
 
3 
 
del(20), del(13), 
del(7) and dup(7) 
 
11.5-14.5% 
 
11.9% 
 
Valli et al., 2011 
a  real specimen, b artificial specimen (a mixture of specimens or DNA from abnormal and normal cases), PB = peripheral blood, BM = bone marrow, 
UC = umbilical cord blood, POC = product of conceptus, CVS = chorionic villi, AF = amniotic fluid 
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Rationale for study 
 
This review has shown the clinical relevance of constitutional (and acquired) 
mosaicism and highlighted the strengths and weaknesses of diagnostic methodologies 
used for mosaicism detection. While exciting results of case reports suggest that array 
technology can be useful for detecting constitutional mosaicism in patients presenting 
with clinical findings, to date, no systematic study of individuals having carefully 
documented proportions of mosaicism has been completed. Therefore, the first aim of 
this study was to determine the effectiveness of array-based technology for detecting 
levels of mosaicism. This aim was achieved by studying individuals having mosaicism 
for Down syndrome for whom the proportion of trisomic cells had been previously well 
documented using FISH methodology. The data obtained from this facet of this study 
allowed for testing the following hypotheses: 
 
1) The relative fluorescence intensities obtained from microarray data, measured by 
the smoothed mean of log2 ratios of all probes across chromosome 21, are 
positively correlated with percentage of trisomic cells determined to be present in 
study samples using FISH methodology. 
 
2) Array-based technology allows for the detection of a trisomic cell population that 
is present in 20% or more cells.  
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A second aim of this study was to gain insight on the effect that trisomy 21 has on 
telomere attrition. Given that people having Down syndrome show signs of premature 
aging and are at risk for developing Alzheimer disease, studies of their cells may provide 
knowledge regarding the relationship between telomere shortening, genomic instability, 
aging and Alzheimer disease. Studies of isogenic trisomic and normal cells from 
individuals having mosaicism for trisomy 21 provide a unique opportunity to evaluate 
effects of trisomy 21 on a trait without confounding influences attributable to differences 
due to age, genomic complement and environment exposure. This study provides the first 
reported measure of both chromosome-specific telomere lengths and the frequency of 
acquired chromosome abnormalities in trisomic cells and isogenic euploid cells obtained 
from the same individuals. The data obtained from this study allowed for testing of 
the following hypotheses: 
 
1) There are differences in telomere lengths between trisomy 21 cells and their 
isogenic euploid cells. 
 
2) These differences in telomere length affect a subset of chromosomes, rather 
than equally affecting all chromosomes. 
 
3) There is an increased frequency of chromosomal instability in the trisomic 
cells compared to euploid cells.  
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Chapter 2 
 
The use of array-based technology for mosaicism detection 
 
Introduction 
  
 Mosaicism is a condition that denotes the presence of two or more cell lines that 
originated from a single zygote, but differ in their genetic make-up as a result of 
nondisjunction or mutation (Thompson and Thompson, 2004). Constitutional mosaicism 
has been observed in both somatic and germ-line tissues in humans. In addition to 
mosaicism, acquired somatic cell chromosomal changes can result in the presence of 
multiple cell lines. The identification of mosaicism/cellular admixture is clinically 
important, with its impact being especially relevant for evaluating cancer specimens, the 
latter of which are becoming one of the largest needs in diagnostic testing.  
  
 Despite its rare incidence, constitutional mosaicism is a formidable diagnostic 
challenge. Mosaicism has been reported for many different chromosomes and many 
different types of abnormalities including monosomy, trisomy, triploidy, deletions, 
duplications, translocations, rings and inversions (Schinzel, 2001). The clinical 
significance of mosaicism has been documented in humans from the prenatal to postnatal 
periods. During very early embryogenesis, chromosomal mosaicism has been shown to 
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be an unexpectedly common event, being seen in 50% to 90% of very early embryos 
studied through in vitro fertilization programs (Bielanska et al., 2002, Daphnis, et al., 
2005; Vanneste et al., 2009; Santos, et al., 2010). Furthermore, about 50% of all 
spontaneous abortions have been conjectured to exhibit chromosomal mosaicism 
(Vorsanova et al., 2005), but this latter value has not been consistently seen by other 
investigators, with the variation in results possibly reflecting, at least in part, 
methodological differences. Mosaicism has also been associated with postnatal 
morbidity, including chromosomal syndromes, mental retardation and multiple congenital 
malformations, autism and schizophrenia. Multiple cell lines arising from acquired 
chromosomal changes have also been observed in a variety of health conditions, 
including but not limited to Alzheimer disease and neoplasia (Youssoufian and Pyeritz, 
2000; Yurov et al., 2008; Schinzel, 2001).  
  
 The tissue-specific distribution and percentage of cells having constitutional 
mosaicism in an individual depends on the timing of the error, the cell lineage(s) 
involved and the survival potential of the cells (Kalousek et al., 2000). The consequences 
of mosaicism for an unbalanced cell line often are associated with greater clinical 
consequences when the error occurs earlier in embryogenesis, since these cases tend to 
have a higher percentage of abnormal cells and/or more tissues involved (especially if the 
error arose prior to cell lineage differentiation). The results of a study reported by Hsu et 
al., 1996 suggested that fetuses with a higher percentage of abnormal cells (>60 per cent) 
were at a higher risk for abnormal outcomes, compared to fetuses with a lower 
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percentage of abnormal cells (< 15 per cent). Often times, individuals with low-level 
mosaicism may be overlooked because they have subtle phenotypes. However, some 
patients with low-level mosaicism have been reported to have clinical outcomes (Yurov 
et al., 2007; Shinawi et al., 2008). In addition, individuals with low-level mosaicism 
could be at an increased risk for conceiving a child with a chromosomal imbalance since 
the aberrant cell line may be present in their gametes (Smith et al., 1962; Hsu et al., 1971; 
Mehes et al., 1973; Kaffe et al., 1974; Richards et al., 1974; Priest et al., 1977; Begleiter 
et al., 1977; Werner et al., 1982; Meschede et al., 1998; Wise et al., 2009; Kovaleva and 
Shaffer, 2003; Herrgård et al., 2007). Similarly, in conditions resulting from acquired 
somatic cell aneuploidy, such as the hematological malignancies, the presence of a small 
clone of cells having a chromosomal aneuploidy and/or rearrangement may be of great 
clinical relevance for the management of the patient’s care, including decisions regarding 
their diagnosis, prognosis prediction and selection of targeted therapeutic options 
(Maciejewski et al., 2009).  
  
 Standard G-banding chromosomal tests may result in low-level mosaicism being 
missed or misinterpreted as a culture artifact, since this analysis is typically limited to the 
assessment of 20 metaphase spreads. G-banding analysis can also result in the failure to 
identify mosaicism due to selective in vitro growth pressure that may favor cells having a 
normal karyotype. When constitutional mosaicism is suspected, for example, due to a 
patient having variegated skin pigmentation, hypomelanosis of Ito and/or growth 
asymmetry (Donnai et al., 1988; Thomas et al., 1989; Woods et al., 1994), or when a 
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small number of cells with significant chromosome abnormalities are detected in the 
initial cytogenetic analysis, the examination of additional cells is usually indicated. In 
general, when 20, 30, or 50 cells are evaluated without detection of mosaicism, the lowest 
level of mosaicism excluded with at least 95% confidence is 14, 10 and 6%, respectively 
(Hook, 1977).  Theoretically, fluorescent in situ hybridization (FISH) is considered to be 
an ideal laboratory technique for detecting mosaicism since cell lines that are present in 
5% or fewer cells can be detected (Papavassiliou, et al., 2009; Dewald, et al., 1998). 
However, scoring FISH is labor intensive, requires precedent knowledge of specific 
chromosome abnormalities and also lacks whole genome coverage.  
 
 Recently, array-based technology has been developed and has shown several 
advantages when compared with other existing techniques used for the analysis of 
chromosomal abnormalities. It allows for genome-wide analysis at the highest resolution 
of less than 700 bp; however, in practice, other parameters may influence the resolution, 
such as experimental “noise” (which is often attributable to DNA fragmentation) and the 
sensitivity of copy number measurements (Bernardini et al., 2010.). In addition to 
improved resolution, another potential advantage of array-based diagnostic testing is that 
cells can be evaluated without potential growth selection that might arise from an in vitro 
culture system. In contrast, routine metaphase chromosome studies to detect 
constitutional chromosomal changes require three (blood) to seven or more (prenatal 
cases; products of conception) days of in vitro cell culture and aberrations that are smaller 
than 3-10 Mb cannot be reliably detected (Shaffer and Bejjani, 2004). Although array-
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based technology has many strengths, it is limited in that it will not allow for the 
detection of balanced chromosomal findings or polyploidy, which can be detected using 
conventional G-banding methodologies. 
  
 Currently, two broad types of array-based technologies are used for clinical 
cytogenetic testing; comparative genomic hybridization arrays (CGH arrays) and single 
nucleotide polymorphism arrays (SNP arrays). In array CGH, patient DNA and control 
DNA are labeled with different fluorochromes and then competitively hybridized to 
arrays having DNA probes (e.g., bacterial artificial chromosomes array [BAC array] or 
synthesized DNA fragments [oligonucleotide array] that are immobilized on glass, chips, 
or beads). The fluorescent intensities of the case to control DNA values are then 
compared to determine copy number alterations across the entire genome. The other type 
of array, a SNP array, was originally designed for whole genome association studies, but 
has been adapted for cytogenetic testing. Given that SNPs are not distributed evenly 
across the genome, several of the original SNP-based microarray platforms were 
modified for cytogenetics testing by incorporating additional copy number probes, the 
latter of which allowed for increased genomic coverage of clinical relevant regions 
(Maciejewski et al., 2009) and better detection of copy number changes. When compared 
to array CGH platforms, SNP arrays have the additional advantage of allowing one to 
simultaneously analyze copy number changes, as well as copy number neutral loss of 
heterozygosity (LOH) and long contiguous stretches of homozygosity (LCSH), thereby 
allowing for the recognition of uniparental disomy (UPD). For assessments using SNP 
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arrays, patient DNA is labeled and hybridized to the microarray, with the results being 
compared with a database of standard reference DNA values.  
  
 While several geneticists have confirmed the ability of array-based technology to 
detect subtle or small abnormalities that were not perceived using conventional 
cytogenetic testing, the ability of array-based technologies to detect the presence of 
mosaicism remains controversial. A number of investigators have reported detecting a 
mosaic complement in blood specimens from individuals that was missed by traditional 
chromosomal analysis techniques (Table 3). Ballif, et al (2006) suggested that the array 
presented an advantage for mosaicism detection since all nucleated blood cell lineages 
could be evaluated (rather than just T-cells following mitogenic stimulation with 
phytohemaglutin, as is the case for conventional cytogenetic testing). The results of case 
reports, have led to a range of estimates regarding the lower detection limits of array-
based technology. Systematic studies that were completed with the goal of evaluating the 
efficacy of array technology for mosaicism detection are few in number. The majority of 
these systematic studies have been performed on “artificial mosaicism” samples that were 
prepared by mixing blood or DNA samples from individuals having a known abnormal 
chromosome complement with normal reference DNA (Ballif et al., 2006; Cheung et al., 
2007; Hoang et al., 2007). Investigators have often elected this approach due to the rarity 
of constitutional mosaicism, which makes it difficult to ascertain multiple patients having 
mosaicism for the same condition. While these laboratory created “mosaic” studies 
provide insight as to the technical strengths of the array assay, they cannot fully mimic 
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the experience that would be encountered when studying individuals having mosaicism, 
the latter of whom might have variable proportions of the different chromosomal 
complements in the total cell population (different cell types as noted above) that are 
present in clinical specimens. Therefore, we carried out a blinded study designed to test 
the efficacy of array-based technologies for detecting the trisomic cell lines present in 
individuals having mosaicism for trisomy 21. The data obtained from this study allowed 
for testing the following hypotheses: 1) The relative fluorescence intensities obtained 
from microarray data, as measured by the smoothed mean of log2 ratios of all probes 
across chromosome 21, are positively correlated with the percentage of trisomic cells 
determined to be present in study samples using FISH methodology (the latter of which is 
currently considered the “gold standard” for mosaicism assessment); and 2) Array-based 
technology allows for the detection of mosaicism of a trisomic cell population that is 
present in 15% or more cells. 
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Materials and Methods 
 
Study Participants 
 The study participants having mosaicism for trisomy 21 were recruited through 
parental support groups [National Down Syndrome Congress (NDSC), the International 
Mosaic Down Syndrome Association (IMDSA) website, newsletters and conferences] 
and through clinical visitations. The only inclusion criterion was that the individual had a 
confirmed diagnosis of mosaicism for trisomy 21 (usually based on GTG-banding studies 
that were completed at or near the time of birth). After providing their informed assent 
(children)/consent (parents or competent adults having mosaicism) (Virginia 
Commonwealth University Institutional Review Board protocol #179), each study 
participant provided a peripheral blood specimen, with some individuals also electing to 
provide buccal smears for FISH studies.  Confirmation and quantitation of the percentage 
of trisomic cells present was done using FISH on cultured and/or uncultured 
lymphocytes, as described below. Blood specimens were also evaluated from positive 
controls (individuals having “complete” trisomy 21) and negative controls (individuals or 
proficiency test specimens (College of American Pathology) having a previous diagnosis 
that showed either a normal complement or a chromosomal finding that did not involve 
chromosome 21). Specimens that were collected from control individuals followed the 
same informed assent /consent procedures as those used for the study participants having 
mosaicism (VCU IRB protocol #179). Prior to array specimen processing, the DNA 
samples were coded to ensure that the investigators were blinded to the karyotype status 
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of the specimens, thereby mimicking the scenario that would occur in the clinical 
evaluation of patients using array technology.  
 
Sample Collection and DNA Extraction 
 Three to five milliliters of peripheral blood was collected from each participant, 
with DNA being extracted following standard procedures (Gentra Puregene, Qiagen, 
Valencia, CA; manufacturer protocol). Prior to microarray analysis, all DNA samples 
were quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). Gel electrophoresis was also used for monitoring 
potential DNA degradation. The quality control criteria used required that all DNA 
samples processed for microarray studies have an OD-260/280 ratio between 1.80 and 
2.00, with a major band size range of approximately10-20 kb. 
 
SNP Array Hybridization and Analysis 
  The Affymetrix Genome-Wide Human SNP Array 6.0 was used for the SNP array 
studies. This platform contains more than 906,600 SNP probes and more than 946,000 
copy number (CN) probes.  Each SNP probe contains 3-4 replicates per allele. The CN 
probes include markers that are distributed evenly across the genome. The median 
distance between probes for SNP and copy number assessments combined is less than 
700 bp (Affymetrix Genome-Wide Human SNP Array 6.0 data sheet). Array experiments 
were performed according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA). 
Briefly, a total of 500 ng of genomic DNA was digested with Nsp I and Sty I restriction 
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enzymes. All fragments resulting from restriction enzyme digestion were ligated to Nsp I 
and Sty I adaptors, which recognize the cohesive 4 base pair overhangs. The adaptor-
ligated DNA fragments were subsequently amplified using a generic primer that 
recognizes the adaptor sequence. PCR amplification products for each restriction enzyme 
digest were combined and purified using magnetic beads (AMPure XP, Agencourt, 
Beckman Coulter, Brea, CA), with the purified PCR products being fragmented with 
DNaseI enzyme and end-labeled using a Terminal Deoxynucleotidyl Transferase (TdT) 
enzymatic reaction. The labeled DNA was hybridized to an Affymetrix Genome-Wide 
Human SNP Array 6.0 overnight.  Following hybridization, the arrays were washed and 
stained with streptavidin phycoerythrin (SAPE) and a biotinylated antibody using a 
Fluidic Station 450. Following staining, the arrays were scanned using a GeneChip 
Scanner 3000 7G.  
  
The sample files generated from the scanner were processed using the Genotyping 
Console Software Version 4.1.0 (Affymetrix, Santa Clara, CA) to assess data quality 
control (QC) and generate copy number files (CNCHP file) for further analysis in the 
Chromosome Analysis Suite Version 1.1 (ChAS) (Affymetrix, Santa Clara, CA). 
Mosaicism was determined by inspection of: 1) the CN value (falling between 2 and 3 for 
this cohort); 2) deviation of the log 2 ratio track from 0 and mean log2 ratio values 
between 0 (2/2 copies) and 0.58 (3/2 copies); 3) alteration of allele difference patterns 
(Figure 2); and 4) a smoothed log 2 ratio value that fell between 2 and 3 (Figure 2). 
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CGH Array Analysis 
 CGH array experiments were performed using a CytoChip array according to the 
manufacturer’s protocol (BlueGnome, Cambridge, UK). Each CytoChip array was 
comprised of 4400 BAC clones with a median size of 565 kb and 1,357 subtelomeric 
clones having a median size of 250 kb. Each clone had 4 replicates via a dye-swap 
experimental design (for disease specific clones, each clone had 6 replicates). Random 
priming was used to label test and reference control DNA samples, according to the 
manufacturer protocol (BlueGnome). Briefly, a total of 800 ng of genomic DNA was 
used, with 400 ng of DNA being labeled with Cy3 and Cy5 dyes, respectively. The same 
quantity and labeling scheme was used for sex opposite reference DNA, the latter of 
which was purchased as a pooled human DNA sample (Promega G1471-male and 
G1521-female). After labeling, the test and reference DNA samples were run through an 
AutoSeqTM G50 column and then checked for DNA yield and dye incorporation using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
After combining the test and reference DNA samples (i.e., Cy3-labeled test DNA and 
Cy5-labeled reference DNA), the DNAs were ethanol precipitated and suppression 
hybridized using human COT-1 DNA and herring sperm DNA in 10% dextran sulphate. 
Following suppression hybridization, the DNAs were hybridized to the CytoChip array 
and incubated at 37°C in a humidified hybridization chamber for 21-24 hours.  Following 
hybridization, non-specifically bound and unbound DNA was removed by washing in a 
2X SSC/0.05% Tween-20 twice at room temperature for 10 minutes each, followed by 
serial washing in 2X SSC/0.05% Tween-20 at 60°C for 5 minutes, 1XSSC at 60°C for 5 
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minutes, 0.1X SSC at 60°C for 5 minutes, and 0.1X SSC at room temperature for 10 
minutes. The array was immediately centrifuged to dry and scanned using a PerkinElmer 
ScanArray Gx PLUS (PerkinElmer Life and Analytical Sciences, Shelton, CT) at 5 µm 
resolution. The intensity data files were analyzed using the BlueFuse for Microarrays 
software (BlueGnome, Cambridge, UK). Mosaicism was recognized by a deviation of the 
log2 ratio values. The negative control specimens are expected to  have a mean log2 ratio 
for chromosome 21 equal to zero, while the expected copy number gain for positive 
controls is 0.58 (a 3/2 ratio). 
 
FISH Methodology 
 FISH was performed using probes specific for chromosome 21 (test probe) and 
chromosome 13 (control probe) to determine the proportion of cells having trisomy for 
chromosome 21. These studies were completed on cultured (72 hours) and uncultured 
(blood smears) leukocyte nuclei as described previously (Papavassiliou, et al., 2009). 
Briefly, for the cultured cell preparations, the slides were serial dehydrated 2 minutes 
each in cold ethanol series (70%, 85%, and 100%). After air-drying, a 10μl aliquot of the 
probe mixture (chromosome 21q22.13-21q22.2 - D21S259\D21S341\D21S1432; 
chromosome 13q14 – RB1)(Abbott, IL) was added to the slides, with the target 
chromatin and probes being co-denatured at 73°C for 2 minutes. Following hybridization 
(at 37ºC for 4-16 hours), the non-specifically bound and excess probes were removed by 
washing (0.4X SSC/0.3% NP-40 solution at 72°C for 2 minutes, followed by 2X 
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SSC/0.1% NP-40 wash solution for 1 minute). The nuclear chromatin was then stained 
using a DAPI/antifade solution (Abbott, IL).   
 For the uncultured preparations, an aliquot of blood was smeared on the slides (20 
l of blood per slide) and air-dried. The slides were serially fixed in a modified Carnoy’s 
fixative (3 parts of methanol and 1 part of acetic acid) at –20○C for 30 minutes. The 
slides were then placed in 90% formamide in 2XSSC solution at 37
○
C for 5 minutes. The 
slides were serial dehydrated for 2 minutes each in an ethanol series (70%, 85%, and 
100%). After air-drying, a 10μl aliquot of the probe mixture (chromosome 21q22.13-
21q22.2 and chromosome 13q14) (Abbott, IL) was added to the slides. The target 
chromatin and probes were co-denatured at 75°C for 10 minutes. Following overnight 
hybridization, excess and unbound probes were removed by serial washing in 0.4XSSC at 
72
 
°C for 2.5 minutes followed by 0.1% NP-40 in PBS at room temperature for 2 
minutes. The nuclei were counterstained with DAPI/antifade solution (Abbott, IL).  
 Probe signals were visualized using a Zeiss Axiskop equipped with single 
(Spectrum Orange, Spectrum Green) and triple band pass filters. In order to detect 
mosaicism levels as low as 5% with greater than 99% power, a total of 1000 cultured 
blood lymphocyte nuclei, and 500 uncultured blood nuclei were scored for each study 
participant (Dewald et al., 1998). 
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Results 
 
SNP arrays were processed for 31 DNA samples, including 13 samples from 
individuals with mosaicism for trisomy 21, 13 samples from individuals having a 
previous diagnosis that showed either a normal complement or a chromosomal finding 
that did not involve chromosome 21 (negative controls) and 5 samples with a previous 
diagnosis of full or partial (due to a structural change that was in every cell) trisomy 21 
by G-banding analysis (positive controls).  BAC arrays were processed on 10 DNA 
samples, including 6 samples from individuals with mosaicism for trisomy 21, 3 samples 
from individuals with chromosome abnormalities that did not involve chromosome 21 
(negative controls) and 1 individual with a previous diagnosis of full trisomy 21 (positive 
control). In a Table 5 a summary of the microarray results obtained from both array 
platforms is presented. The results of each case are compared to previous cytogenetic 
analyses and indicate the percent mosaicism observed by the FISH compared to 
microarray methodologies. 
 
As expected, the CN for chromosome 21 detected in each of the negative control 
cases was equivalent to 2 (no aberrations noted).  In addition, abnormalities involving 
other chromosomes that were present in these cases were correctly identified with no 
additional clinically relevant aberrations being detected. The background level of cells 
having gains involving chromosome 21 based on the SNP microarray analysis in the 
negative control group ranged from 0% to 4%. Using only the CN state values calculated 
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by the ChAS software (which has criteria requiring 30% or higher mosaicism for 
detection), only 5 of the 13 mosaic cases were detected, with their estimated  percentage 
of trisomic cells ranging from 28% to 100%. By expanding the ChAS software analysis 
to include an assessment of the smoothed signal, a total of 8 of the 13 individuals with 
mosaicism were readily identified as having mosaicism, with a case having 15% trisomic 
cells being detected. A mosaic case having 10% trisomic cells showed subtle changes 
from the non-mosaic cases, but yielded a value that was equivocal and thus not clearly 
defined as mosaicism (Figure 2). In two individuals having approximately 19% trisomic 
cells as determined by FISH, the SNP array patterns were within normal limits (false 
negative). Interestingly, two individuals with mosaicism involving approximately 80% 
trisomic cells, as determined by FISH, had an array value that was consistent with non-
mosaic (“full”) trisomy 21.  
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Table 5: Summary of microarray results in 30 study subjects 
Karyotype 
%FISH 
Affymetrix Genome-Wide Human SNP 6.0 BlueGnome CytoChip 
Gain for ch.21 detected 
%Array 
Smooth signal 
of ch.21 
Mean  
log2 
ratio of 
ch.21 
 
Gain for 
ch.21 
detected 
log2 ratio of 
ch.21 
CPB UPB 
 
Log2 
ratio 
 
Allele 
difference 
 
Smooth 
signal 
CN 
calling 
Mean  SD Mean SD 
Negative Controls (2 copies ch.21 in all cells)              
46,XY,del(3)(q29)   N N N N 3 2.025 0.124 0.008 N 0.003 0.058 
46,XX,dup(3)(q26.1),del(8)(p23.2)   N N N N 0 1.980 0.127 -0.010 N 0.015 0.048 
46,XY,dup(16)(q22.2q23.2)   N N N N 4 2.036 0.233 0.009 N 0.009 0.057 
46,XY,dup(10)(p13p15.3)   N N N N 0 1.995 0.386 -0.003    
46,XY,del(18)(p11.2)   N N N N 2 2.016 0.089 0.006    
46,XY,del(8)(p23.1p23.3),dup(8)(p21.1p22)   N N N N 0 1.907 0.123 -0.040    
46,XX   N N N N 0 1.895 0.155 -0.045    
46,XY   N N N N 0 1.941 0.153 -0.026    
46,XX,del(17)(p11.2p12 )   N N N N 3 2.030 0.139 0.010 N -0.024 0.075 
46,XX   N N N N 3 2.028 0.153 0.009 N -0.030 0.059 
46,XY,del(2)(q14.1q14.3),dup(22)(q11.21q11.21)   N N N N 2 2.023 0.121 0.008    
46,XY,dup(5)(q33.3q35.3),del(13)(q34)   N N N N 1 2.014 0.123 0.004    
46,XY,dup(17)(p11.2p12),del(17)(q11.2q12)   N N N N 3 2.033 0.112 0.012 N 0.012 0.041 
Mosaic Tri 21              
mos 47,XX,+21/46,XX 93.6 80.4 Y Y Y Y 100 3.088 0.178 0.347 Y 0.381 0.064 
mos 47,XY,+21/46,XY 50.5 63.2 Y Y Y Y 50 2.498 0.147 0.177 Y 0.216 0.083 
mos 47,XY,+21/46,XY 48 26 Y Y Y N 21 2.212 0.155 0.079 N -0.049 0.102 
mos 47,XX,+21/46,XX 90.5 78.5 Y Y Y Y 100 3.160 0.183 0.365    
mos 47,XX,+21/46,XX 24.9 28 N N S N 7 2.068 0.150 0.025    
mos 47,XX,+21/46,XX 21 19.4 N N N N 0 1.970 0.140 -0.014    
mos 47,XX,+21/46,XX 18.7 19 N N N N 0 1.960 0.151 -0.018    
mos 47,XY,+21/46,XY 29.5  Y Y Y N 20 2.199 0.146 0.074    
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Table 5: Summary of microarray results in 31 study subjects (continued) 
Karyotype 
%FISH 
Affymetrix Genome-Wide Human SNP 6.0 BlueGnome CytoChip 
Gain for ch.21 detected 
% Array 
Smooth signal 
of ch.21 
Mean  
log2 
ratio of 
ch.21 
 
Gain for 
ch.21 
detected 
log2 ratio of 
ch.21 
CPB UPB Log2 
ratio 
Allele 
difference 
Smooth 
signal 
CN 
calling 
Mean  SD Mean SD 
Mosaic Tri 21              
mos 47,XY,+21/46,XY 62 53 Y Y Y Y 66 2.659 0.157 0.227    
mos 47,XX,+21/46,XX 23.2 20 S N Y N 15 2.147 0.141 0.055    
mos 47,XY,+21/46,XY 6.5 17 N N S N 8 2.079 0.131 0.030    
mos 47,XX,+21/46,XX 43 41 Y Y Y Y 28 2.279 0.223 0.101    
mos 47,XY,+21/46,XY 10.4 8.5 N N S N 10 2.099 0.150 0.037    
Positive control (3 copies of ch.21 in all cells)              
47,XX,+21 96.8 89.4 Y Y Y Y 100 3.181 0.272 0.369 Y 0.357 0.047 
47,XY,der(21)(q10;q10) 81.5  Y Y Y Y 51 2.511 0.282 0.177    
47,XY,+21 97.6  Y Y Y Y 100 3.162 0.236 0.365    
47,XX,+21 97.2  Y Y Y Y 100 3.072 0.236 0.342    
46,XX,der(21)(qter→q21::p11.1→qter)   Y Y Y Y 100 3.051 0.188 0.242    
ch.21 = chromosome 21, Tri 21 = trisomy 21, CPB = cultured peripheral blood, UPB = uncultured peripheral blood, CN = copy number, SD = 
standard deviation, Y = yes, N = no, S = suspicious 
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In practice, the manufacturer recommended protocol for detecting mosaicism in a 
specimen is to combine the data collected from all analyses, including the log2 ratios, 
smoothed signals and especially the allelic patterns. By expanding the assessments to 
include each of thesfore data points, the current version of the ChAS software 
consistently allowed for the detection of a minor cell population that was present in 
approximately 20% of cells (20% to 80% trisomic complement)(Figure 2).  
 
 
 
48 
 
 
Figure 2: Composite array results of representative cases having mosaicism for trisomy21. Each box in this figure 
represents a different individual, with a total of 8 patients being shown. The percentage values below the data indicate the level 
of trisomic cells present in each person, with 0% representing an individual having a normal (2 copies) complement for 
chromosome 21 and 100% representing an individual with “complete” trisomy 21. The results of the ChAS findings from 
different analyses are shown, including the log2 ratio (a); the allelic patterns (b) and the smoothed signal (c). The  mean log 2 
ratios (a) are shown as a light blue line in the middle of the marker data values and range from 0 (0% trisomy) to 0.6 (100% 
trisomy). (b). The allele difference track shows allele patterns observed in euploid ( where A allele = 0.5 and B allele = -0.5 
and AA = 1; AB = 0;  and BB = -1) compared to trisomic (AAA = 1.5, AAB = 0.5, ABB = -0.5 and BBB = -1.5) cells. (c) The 
smooth signal of log2 ratio track shows an increase of the signal from 2 to 3, corresponding with 2 to 3 copies of chromosome 
21. 
  
(a) 
(b) 
(c) 
0.6 
1.5 
0.5 
-0.5 
-1.5 
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For the positive control cases, the SNP array evaluation of 4 of the 5 specimens 
was consistent with the GTG banding karyotypic results. However, one case, who was 
referred for assessment due to a phenotype suggestive of mosaicism (presence of 
hypomelanosis of Ito), had an array result that was discrepant to the findings of the 
conventional cytogenetic analysis. The chromosome analysis showed the presence of 
secondary trisomy for chromosome 21 [der(21)(q10;q10); either an isochromosome or a 
Robertsonian translocation] in each of the 30 metaphase spreads examined (100%). 
Interestingly, the array result was consistent with the presence of trisomy mosaicism for 
both chromosome 14 (62% of cells) and chromosome 21 (51% of cells). To 
confirm/refute these array findings, additional analyses were completed using FISH with 
two probe sets. Probe set one included a probe that was specific for the long arm of 
chromosome 14 (specific for 14q.32; spans the IGH region), with a control probe also 
being evaluated (specific for band 11q13; spans the CCND1 breakpoint region). Probe set 
two included a probe that is specific for band 21q22 (D21S259\D21S341\D21S1432), 
along with a control probe from chromosome 13 (spans the 13q14; RB1locus) (Figure 3). 
An assessment of 500 interphase nuclei per probe set confirmed the presence of 
mosaicism for both chromosomes, with three signals being present for the chromosome 
14 probe in 22% of intephase nuclei and three signals for the chromosome 21 probe in 
81.5% of interphase nuclei. 
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Figure 3: Detection of mosaicism for trisomy 14 and a trisomic dose of 21q. Mosaicism was determined from CN state (1), 
log2 ratio (2), allele difference (3) and smooth signal (4) tracks for chromosome 14 (a) and chromosome 21 (b). Interphase 
analysis on cultured lymphocytes (c), using a locus specific probe mixture for chromosome 14 (green) and for chromosome 11 
(red) showed cells having 3 (lower left) or 2 (upper right) signals for the chromosome 14 probe. Interphase analysis on 
cultured lymphocytes (d), using a locus specific probe mixture for chromosome 21 (red) and for chromosome 13 (green) 
showed cells with 3 (lower right) and 2 (upper left) signals for chromosome 21. (e) Metaphase spread showing a trisomic dose 
of the long arm of chromosome 21 due to a der(21)(q10;q10). 
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A SNP array was also processed using a DNA sample from an individual with 
partial trisomy for chromosome 21, which resulted in her having a trisomic dose of  
21q21 to 21qter (Figure 4).  The array result was consistent with the findings of the GTG-
banding and allowed for refinement of the breakpoint in the rearrangement to band 
21q21.2 (Figure 4).  
 
A potential advantage for using a SNP array was illustrated by a case having 
mosacism with 20% of cells that were trisomic based on the array analysis (Figure 5). In 
this specimen an allelic pattern consistent with the presence of 3 distinct chromosomes 21 
was seen for the proximal long arm markers, with the distal long arm markers showing a 
shift in the allele pattern that could indicate the location of a meiotic recombinational 
event (Figure 5).  
 
The collective information gained from the assessments of the mosaic probands 
and the positive and negative control subjects, was used to determine if the proportion of 
trisomic cells estimated from the SNP array, as measured by the smoothed mean of log2 
ratios of all probes across chromosome 21, correlated with the percentage of trisomic 
cells determined by the “gold standard” FISH methodology (Figure 6). These values were 
positively correlated, with  no significant difference being detected in the  percentage of 
trisomic cells quantified using the SNP array compared to the FISH analysis that was 
completed on uncultured lymphocytes (p-value = 0.80, paired t-test), or on the cultured 
lymphocytes (p-value = 0.30, paired t-test).  
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Figure 4: SNP array result of an individual with partial trisomy for chromosome 21 due to a structural abnormality. 
Note the increased log2 ratio, and smooth signal, and altered allele difference pattern at 21q21.2 (position 24,959,394) (arrow) 
with 3 doses continuing for the rest of the long arm. The SNP array result is in agreement with the findings of the GTG-
banding analysis which showed a partial trisomy, with a breakpoint at 21q21 (as evidenced by the reduced thickness of the 
21q21 dark band in the upper portion of the derivative chromosome 21 when compared to the bottom portion of the derivative 
chromosome).  
 
 
 
 
 
 
 
 
 
46,XX,der(21)(qter→q21::p11.1→qter) 
CN state 
Log2 Ratio 
Allele Difference 
Smooth Signal 
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Figure 5: SNP array result of chromosome 21 showing an altered allelic pattern. Probable meiotic recombination events 
involving loci at 21q21.3 (position 29,989,702-31,288,209) (small arrows), and 21q22.12 (position 37,050,935-47,983,657) 
(large arrows) occurred during meiosis I, leading to alterations in the allelic patterns in this individual with 20% of trisomy 
21cells.
CN state 
Log2 Ratio 
Allele Difference 
Smooth Signal 
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Figure 6: Mean of smoothed log2 ratios of all probes across chromosome 21 and 
percentage of trisomy 21 cells as determined by FISH. The data are shown with the 
mean and SD of the smoothed log2 ratios for the  negative controls (blue), individuals 
with mosaicism for trisomy 21 (red) and positive trisomic controls (green). The blue box 
shows zone of normal copy number (CN of 2), the pink box shows the mosaicism zone 
and the green box shows the zone of complete trisomy 21 (CN of 3). Note the positive 
correlation between mean of the smoothed log2 ratios and percentage of trisomic cells 
(Pearson correlation, r = 0.88, p-value <0.00001). 
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The BAC array CGH platform was used to process a total of 10 DNA samples, 
including 6 negative control samples, 3 samples from individuals with mosaicism for 
trisomy 21 and 1 sample from an individual with full trisomy 21 (Table 5 and Figure 7). 
The BAC array provided findings that were consistent with those of conventional G-
banding results for each of the negative control cases, with no gain of chromosome 21 
being detected in any of these samples. A gain of chromosome 21 was detected in the full 
trisomy 21sample and in 2 of the 3 mosaic cases. The mosaic case that was not readily 
identified had 26% trisomic cells in the FISH assay and did show a subtle deviation of the 
log2 ratio, but this variance was too equivocal to allow for clear categorization as a 
mosaic case (Figure 7b). This same patient was correctly categorized as a mosaic using 
the SNP array.   
  
 A comparison of the potential correlation between trisomic values detected using 
the BAC array compared to FISH analyses and the SNP array was completed (Figure 8).  
The estimates of trisomic cells present in individuals (based on the mean log2 ratio of all 
probes across chromosome 21) from both array platforms were positively correlated with 
the values obtained in the FISH assay. Furthermore, for 2 of the 3 mosaic cases evaluated 
with both platforms, there was good agreement for the estimated proportion of trisomic 
cells present.  
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Figure 7: Array CGH results for chromosome 21 using a BAC array platform. This figure shows the results from 5 
subjects including: (a) an individual with a normal chromosome 21 complement (log 2 ratio of 0 as expected with 2 copies); 
(b) an individual with 26% trisomic cells determined by FISH on uncultured lymphocytes, which shows subtle deviations from 
the log2 ratio (suggestive of mosaicism but not definitive); (c) an individual with 50% trisomic cells as  determined using FISH 
on uncultured lymphocytes, which shows gains (log 2 ratio of 0.3 or more) for several of the BACs evaluated from 
chromosome 21 (green line);  (d) an individual with 80% trisomic cells on uncultured lymphocytes, showing a value consistent 
with “full” trisomy  21; and (e) an individual with “full” trisomy 21 that has a log 2 ratio  consistent with trisomy 21 (but less 
than the theoretical value of 0.58 as expected for 3/2 copies).
(a) (b) (c) 
(d) (e) 
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Figure 8: Comparison of the proportion of trisomic cells detected using SNP array, 
BAC array and FISH methodologies. The mean log2 ratios for chromosome 21 from 
SNP (○) or BAC (∆) arrays are presented on the X axis, with the percentage of trisomic 
cells as determined using FISH, being presented on the Y axis. The data points shown for 
each individual are the mean values for the negative controls (blue), individuals with 
mosaicism for trisomy 21 (red) and positive controls (green). Note the nearly parallel 
trend lines of the SNP (dashed line) and BAC (solid line) platforms.   
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Discussion 
 
 These studies have shown that array-based technology has both strengths and 
weaknesses in its ability to detect the presence of chromosomal mosaicism. Using the 
default software analysis setting for CN state, we were unable to detect trisomic cell 
populations that were present in less than 30%, due to the software categorization of log2 
ratio changes from 0-30% as copy number neutral findings. Thus, it is important to 
include analyses of mosaic cases in laboratory validation studies to ensure that the 
software criteria are defined in a manner that is congruent with the level of detection for 
mosaicism that is desired by the lab. In addition to log2 ratio values, SNP arrays provide 
information about the allelic patterns present in each case. While these patterns were very 
useful for confirming suspected cases of mosaicism, in our experience the use of allele 
pattern assessments did not allow for the recognition of additional cases that were 
undetected using the log2 ratios, or the smoothed signal values.   
 
 For the SNP microarray platform (Affymetrix 6.0) and analysis software (ChAS) 
used, the smooth signal assessment tool provided the most efficient means for detecting 
mosaicism. Based on the collective information gained from all assessment tools for the 
13 cases evaluated, no significant difference was detected in the quantitative percentage 
of trisomic cells estimated using microarray compared to FISH technologies. However, 
categorically, the microarray studies resulted in 2 false negative diagnoses (with both 
cases having less than 20% trisomic cells) and 2 cases that would have been misclassified 
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as “full” trisomy that were truly mosaic (80% or more trisomic cells). Furthermore, for 3 
cases (2 of which had approximately 10% trisomic cell populations), detection of the 
trisomic cell line was subtle/equivocal and limited to an assessment of the smooth signal 
value and would have been missed using the other analysis assessments. Nonetheless, 
these specimens were distinguished as candidates for additional reflex testing with FISH 
to confirm/refute the possible presence of low level mosaicism. However, without 
experience in scoring mosaic cases, these subtle results may well have been misclassified 
as normal, which would have reduced the sensitivity to 0.62. Therefore, as noted above, it 
is important that geneticists who are interpreting the results of microarray findings gain 
experience in the assessment of cases having mosaicism to improve the likelihood that 
they will recognize cases.  
 
There are several explanations for the incongruity between microarray and FISH 
and/or G-banding studies. Firstly, the DNA used for the microarray studies is collected 
from all types of leukocytes, while the G-banding studies are performed on T 
lymphocytes, (following ohytohemaglutinin [PHA] stimulation). Secondly, it is possible 
that in vitro selective growth differentials contribute to the discrepancy. Thirdly, the cells 
evaluated in the microarray studies represent a composite of the total cell population 
(average) value, whereas the FISH analyses allow for the recognition of single cell 
aberrations, making FISH the more sensitive technology for detection of mosaicism if a 
known target can be anticipated. 
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Using the current software analysis tool sets supplied by the array vendors, this 
study showed that levels of mosaicism that were greater than 15% to 20% were 
consistently detected (Figure 2). This result is in close agreement with the findings of 
previous investigators who denoted the ability to detect cell mixtures synthesized to have 
10% to 20% “mosaicism” using array CGH platforms (Ballif et al., 2006; Cheung et al., 
2007; Hoang et al., 2007). In one investigation, a SNP array was reported to be have the 
ability to detect  mosaic cell lines that were present in as few as 5% of the total cell 
population (Conlin, et al., 2010). These investigators suggested that a key advantage of 
using a SNP array for mosaicism detection is that one has allelic patterns, as well as copy 
number changes, to aid in the interpretation of cell lines having mosaicism (Conlin, et al., 
2010).   
 
In this study, we demonstrated that both the BAC and SNP platforms could detect 
mosaicism, with their results being consistent for two of the three cases evaluated using 
both platforms. This inability to identify the one case having mosaicism using a BAC 
array could be explained by the smaller number of probes analyzed for chromosome 21 
(52 BAC clones versus 24,170 SNP and CN probes). However, this study was not 
designed to compare the performance between SNP and BAC arrays, since the number of 
study subjects (31 cases versus 10 cases) varied between platforms, being limited to only 
3 cases having mosaicism for the BAC array (due to cost limitations). 
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 While limitations of arrays for identifying mosaicism were observed in this study, 
it also showed the strength of array-based technology to identify previously unrecognized 
chromosomal mosaicism. Specifically, the array studies allowed for the detection of 
mosaicism for trisomy 14 that was not identified in a conventional GTG-banding study. 
However, an assessment of the percentage of  trisomic cells present in this specimen 
varied between the FISH and SNP array assays, with the percentage in arrays being 
higher for trisomy 14 (62% compared to 22%) and lower for trisomy 21 (51% arrays; 
81.5% FISH; 100% GTG-banding). Possible explanations for the observed variations in 
frequencies of cell lines include: (1) selective growth pressure against the trisomy 14 
cells in the in vitro culture system used for the FISH and GTG-banding studies;  (2) a 
higher proportion of trisomy 14 complements in the total leukocyte cell population when 
compared to the T-cell population, the latter of which is preferentially present in the in 
vitro cultures due to stimulation using PHA; or (3) a potential influence of having used an 
archival heparinized blood specimen for the DNA extraction. 
 
One major advantage for using a SNP array is that, when combined with parental 
studies, one can infer the origin of the segregation error (i.e., meiosis I versus meiosis II 
and mitosis) that resulted in the presence of the extra chromosome in the trisomic 
individuals. However, these patterns were difficult to distinguish when the percentage of 
trisomic cells was low. When the proportion of trisomic cells was 50% or more, one 
could confidently differentiate between meiosis I and meiosis II/mitosis errors. Also, an 
analysis of alleleic patterns can allow for the recognition of recombination events, which 
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can be helpful for confirming the presence of mosaicism in specimens having less than 
50% trisomic cells, as seen in Figure 5.  
 
In summary, our study demonstrates that array-based technology is effective for 
detecting mosaicism that is present in 20% or more cells. However, FISH remains the 
“gold standard” for mosaicism detection and should be considered for confirmation when 
low level mosaicism is suspected and/or to confirm/refute equivocal array-based results. 
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Chapter 3 
 
Chromosome-specific telomere length profiles in euploid and trisomic cells obtained 
from individuals having mosaicism for Down syndrome  
 
Introduction 
 
 The growing number of elderly individuals in our population has caused an 
increased concern about the management of future healthcare needs and costs. It has been 
estimated that the number of people aged 65 years or older will increase from 
approximately 35 million in 2000 to 71 million in 2030, with the number of people who 
are age 80 years or older being expected to increase from 9.3 million in 2000 to 19.5 
million in 2030 (www.cdc.gov/mmwr/).This increase in our need for services related to 
aging individuals underscores the necessity to have a better understanding of the 
mechanisms of aging and age-related health conditions, with the ultimate goal of  
improving our ability to diagnosis, treat and possibly prevent age-related diseases such as 
cancers, and neurodegenerative diseases (i.e., Alzheimer disease). To better understand 
the mechanisms underlying aging and age-related diseases, different study models have 
been utilized. For example, investigators have studied biological measures collected from 
centenarians or other older individuals compared to those observed in young individuals. 
However, interpretation of the results of these studies can be confounded by differences 
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in genetic backgrounds, environmental exposures and co-existing health conditions. One 
approach that can be used to test the contribution of genes on the aging phenotype is to 
study individuals who have mutations that cause them to have premature aging, such as 
Hutchinson–Gilford Progeria syndrome and Werner syndrome (Crabbe, et al., 2007; 
Ariyoshi, et al., 2007; Cao, et al. 2011). Individuals with Down syndrome have also been 
observed to age prematurely. In particular, people with Down syndrome have an 
increased risk for developing an early onset of Alzheimer disease (Potter, 1991; Roth et 
al., 1996). 
  
  The results of the many studies focused on understanding aging have shown that 
both genetic and environmental factors play an important role in the etiology of normal 
aging and the acquisition of age-related conditions in humans. One genetic factor that has 
been implicated in the aging process and development of age-related diseases is the 
shortening of telomeres. A telomere is a specialized structure at the end of a chromosome 
that consists of tandem repeats (TTAGGG/CCCTAA)n and telomere associated proteins, 
including  TRF1, TRF2, TIN2, TPP1, Rap1 and POT1 (Aubert and Lansdorp, 2008). 
Telomeres play an important role in maintaining structural integrity of chromosomes by 
keeping the chromosome ends intact and preventing the single stranded tip that results 
from incomplete replication from being recognized as DNA damage (Blackburn, 2005). 
 
 The protective function of the telomere was first recognized by Muller (1938) and 
McClintock (1941). McClintock noted that without a telomere, a chromosome’s ends 
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would fuse and causes genomic instability. In 1961, Hayflick and Moorhead 
demonstrated that cultured cells have a limited number of divisions they complete before 
entering a senescence phase. This phenomenon is known as the “Hayflick limit”. In 1973, 
Olovnikov was the first to recognize the “end replication problem”. He proposed that 
following each round of replication, cells lose small segments of DNA due to DNA 
polymerase being unable to fully replicate the chromosome ends. This phenomenon is 
ultimately thought to lead to cell death when telomeres reach critically short lengths. At 
the cellular level, the mechanism whereby telomere shortening triggers replicative 
senescence and cell death is unclear. It has been speculated that telomere shortening may 
trigger a TP53 DNA damage response (Davis et al., 2003).  
  
 Telomere attrition has been conjectured to play a causal role in aging (Mayer  et 
al., 2006) and has also been associated with a number of health conditions, including, but 
not limited to, neoplasms (de Lange, 1994; Shay, et al., 1993;Autexier and Greider, 1996; 
Blackburn, 2005; Gerashchenko, 2010; Ma, et al., 2011, Donate and Blasco, 2011); 
atherosclerosis (Benetos et al., 2004); heart failure (Wong et al., 2008); obesity (Valdes, 
et al., 2005); rheumatoid arthritis (Schonland et al., 2003); stress (Epel et al., 2004); 
chronic schizophrenia (Yu et al. 2008); dyskeratosis congenita (Vulliamy et al., 2004); 
Alzheimer disease (Panossian et al. 2003); premature aging syndromes (such as 
Hutchinson–Gilford Progeria syndrome and Werner syndrome [Crabbe et al., 2007; 
Ariyoshi et al., 2007; Cao, et al., 2011]); chromosome instability syndromes (such as 
ataxia telangiectasia, Bloom syndrome and Fanconi anemia [reviewed in Callén and 
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Surrallés, 2004]); and Down syndrome (Vaziri et al., 2003; Jenkins et al., 2006; Jenkins 
et al., 2008). Telomere length has also been speculated to influence mortality (Cawthon, 
et al., 2003). 
 
 In most somatic cells, the telomere shortens with each cell division due to the end 
replication problem. This shortening is thought to occur in cells that lack telomerase. 
Telomerase, which was discovered by Blackburn and colleagues (Greider and 
Blackburn,1985; Shampay and Blackburn 1988; Greider and Blackburn, 1989), is a 
specialized enzyme that maintains telomere length by adding TTAGGG repeat sequence 
to the 3' end of DNA strands in the telomere regions, thus maintaining telomere length 
(reviewed in Chan and Blackburn, 2004; Aubert and Lansdorp 2008). Telomerase 
activity is present in germ cells, but not in most somatic cells, leading to somatic cells 
having a limited lifespan. However, in some cell types, telomere length can be 
maintained by an alternative pathway (ALT) involving homologous recombination 
between telomeric or subtelomeric sequences (reviewed in Mefford and Trask, 2002). 
 
 Besides the end replication problem, investigators have shown that oxidative 
damage of the telomeric sequence could be a major cause of telomere shortening. This 
finding was supported by antioxidant treatment with a free radical scavenger, which was 
able to reduce telomere shortening in cultured fibroblasts (Von Zglinicki, 2000). One of 
the key enzymes involved in free-radical metabolism is superoxide dismutase (SOD-1), 
which is encoded by the SOD-1 gene on chromosome 21. In individuals with Down 
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syndrome, SOD-1 activity is increased due to triplication of chromosome 21, with this 
increase being disproportionate to the activity of the downstream enzymes responsible for 
removal of hydrogen peroxide (e.g., glutathione peroxidase). It has been speculated that 
this imbalance may contribute to premature telomere damage in trisomy 21 cells by an 
accumulation of hydrogen peroxide.  
 
 To date, only a few investigators have studied the relationship between telomere 
length and Down syndrome. Using a terminal restriction fragment (TRF) telomere assay, 
which provides an overall average telomere length, Vaziri et al. (1993) observed a 
significantly higher rate of telomere loss (133 ± 15 bp/year) in people having Down 
syndrome compared with age-matched controls (41 ± 7.7 bp/year). In addition, 
individuals with Down syndrome who have dementia/Alzheimer disease or mild 
cognitive impairment have been reported to have shorter telomeres than individuals with 
Down syndrome without these conditions (Jenkins et al, 2006; Jenkins et al., 2008). One 
limitation in interpreting the results from these previous studies is that the observed 
differences in telomere length (which is a heteromorphic trait) reflect variations between 
unrelated individuals who, in addition to having Down syndrome, also have differences 
in their genetic make-up and environmental exposure histories.  
  
 Twin studies, comparing identical to non-identical twins or identical twins who 
are discordant for a phenotype/exposure, are one of the most powerful model systems for 
teasing apart the contribution of genetic versus environmental influences on a trait. 
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Another interesting experimental approach for recognizing genetic differences 
attributable to genetic imbalance is to study individuals having mosaicism, because an 
individual with mosaicism has 2 or more genetically distinct cell lines that develop within 
a single zygote and differ only by chromosomal nondisjunction. Despite it is rarity, 
mosaicism for trisomy 21 is a fascinating condition to study for gaining insight about 
aging and Alzheimer disease since individuals with mosaicism have two types of cells 
(i.e., euploid and trisomy 21) that are identical for environmental exposure and nearly 
identical for their genetic background (i.e., only different by the  number of chromosomes 
21).  
 
 Therefore, this study was performed to evaluate the impact of having a trisomic 
dose of chromosome 21 on telomere length. By comparing trisomic to euploid cells from 
individuals having mosaicism for Down syndrome, one could minimize inter-individual 
differences arising from other genetic/environmental influences. In addition, by utilizing 
FISH methodology with a telomere-specific probe on metaphase chromosomes, 
combined with comparative genomic hybridization (CGH) technology, one can compare 
“chromosome-specific” telomere lengths from euploid cells to trisomic cells obtained 
from individuals having mosaicism for trisomy 21. Lastly, while there have been 
previous reports of telomere lengths in older individuals having Down syndrome, there 
have been no reports of the telomere lengths in children. The data derived from this study 
allowed for a direct testing of the following hypotheses: (1) Differences in telomere 
length can be detected between cell types based on their genetic make-up; (2) Telomeres 
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are shorter in cells having a trisomic dose of chromosome 21 compared to cells having a 
euploid (2 copies) dose; (3) Telomere attrition can be observed as a biological change 
that occurs during early childhood in a cell having a trisomy 21 complement; (4)  
Telomere attrition associated with trisomy 21 affects all chromosome equally, rather than 
having a targeted effect on a subset of chromosomes. 
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Materials and Methods 
 
Study Participants 
Participants were recruited through the National Down Syndrome Congress 
(NDSC) meeting (Washington D.C., 1995), announcements made in national and local 
Down syndrome support groups, newsletters, the International Mosaic Down Syndrome 
Association (IMDSA) (via their website and IMDSA conferences) and through visits for 
genetic counseling. The only inclusion criterion for study participation was that the 
individual had a confirmed diagnosis of mosaicism for trisomy 21.  All families have 
given informed consent to participate in this study, which has been approved by the 
Virginia Commonwealth University Institutional Review Board (protocol #179). 
 
Cell Cultures 
Duplicate stimulated lymphocyte cultures were established and harvested 
according to standard protocols [RPMI 1640 media, supplemented with 15% fetal bovine 
serum (FBS) and phytohemaglutinin (PHA)]. A total of 72 hours after culture initiation, 
the lymphocyte cultures were harvested as described previously, with colcemid being 
added 15 minutes prior to harvest to enrich the specimens for cells that were in the 
mitosis portion of the cell cycle (Leach and Jackson-Cook, 2001).  
 
The lymphocyte chromosome preparations that were used in this study were 
obtained from archival cell pellets that were harvested from 2004 to 2009. These archival 
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pellets were kept in a modified Carnoy’s fixative (3 parts of methanol and 1 part of acetic 
acid) at -20
o
C.  To reduce cytoplasm, which might compromise probe hybridization, the 
cell pellets were washed in Carnoy’s fixative twice before the cell solutions were dropped 
onto the slides using a Thermatron (temperature of 22±1C and humidity of 48±2%). The 
slides were reviewed with a phase contrast/bright field microscope to ensure that the 
quality of the preparation was adequate for the FISH study (number of 
metaphases/interphase nuclei and quality of preparation [lack of cytoplasm]). After 
review, the slides were placed on a hot plate at 60C for an hour, followed by aging at 
room temperature for 1-2 weeks. Alternatively, rather than aging at room temperature, for 
a portion of the cells the aging was induced by soaking the slides in 2xSSC for 10 
minutes prior to the FISH experiment. If cytoplasm was present, the slides were soaked in 
Carnoy’s fixative for 1 additional hour before proceeding with probe hybridization. 
 
Chromosome-Specific Telomere Length Assay 
Metaphase chromosomes were hybridized with a telomere-specific FITC-labeled 
synthetic peptide nucleic acid (PNA) probe following the manufacturer’s protocol 
(DakoCytomation, Denmark). In addition, an FITC-labeled probe that is specific for the 
pericentromeric region of chromosome 2 was simultaneously hybridized to the metaphase 
spreads as a control (and to serve for standardization of intensity values from cell to cell) 
(Mayer et al., 2006). Briefly, slides were fixed in cold Carnoy’s fixative for 1 hour. After 
air-drying, the slides were rinsed with 1xTBS (Tris-Buffered Saline, pH 7.5) for 2 
minutes, fixed in 3.7% formaldehyde in 1xTBS for 2 minutes and then rinsed (twice in 
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1xTBS for 5 minutes). The slides were then immersed in a pre-treatment solution 
containing proteinase K, for 10 minutes, rinsed (twice in 1xTBS for 5 minutes) and 
dehydrated (using a cold ethanol series [70%, 85% and 100%]). After air-drying, a 
cocktail probe mixture (11µl of FITC-labeled telomere specific probe and 1 µl of FITC-
labeled centromere-2 probe  per subject [a half slide area]) was added to each slide and 
the probe and metaphase spreads co-denatured in a thermocycler at 80
o
C for 3 minutes. 
After hybridization in a dry hybridization chamber at room temperature for 2 hours, the 
excess and unbound probe was removed by rinsing (once in a manufacturer provided 
rinse solution at room temperature for 1 minute, followed by 5 minutes in a manufacturer 
provided wash solution at 65
o
C). Following serial dehydration in a cold ethanol series 
(70%, 85% and 100%), the slides were air-dried and counterstained with a 5:1 
DAPI/propidium iodide solution. 
 
The telomere lengths of each chromosome were assessed using a semi-
quantitative FISH method (CGH software from Applied Imaging Cytovision System) as 
described by Leach et al. (2004). Briefly, three images were captured with a CCD camera 
for each metaphase: (1) a reverse DAPI image, which allows for chromosome 
identification and subsequent karyotyping; (2) a test/ FITC image, showing telomeric and 
centromeric probe signals; and (3) a reference/ propidium iodide image that allows for 
visualization of the chromosome body. Fluorescent intensities obtained from the “test” 
and “reference” images were used for calculating the ratio profiles of relative telomere 
intensity for each chromosome arm. Overlapping telomeres or telomeres that were in 
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close proximity were excluded from the analysis. For each person the intensity values 
were averaged over 20 homologs from 10 euploid cells and 20 homologs from trisomic 
cells (30 homologs for chromosome 21). A representative metaphase stained with 
telomeric probe and centromeric probe for chromosome 2 with DAPI/PI counterstain is 
shown in Figure 9. 
  
Cen-2 intensities of all individuals were standardized to a value of 4, and the 
respective telomere lengths for each person adjusted proportionally. All statistical 
analyses were performed using the R statistical software program. 
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Figure 9: Representative images showing FISH-based quantification of 
chromosome-specific telomere intensity. Image (a) is a metaphase spread stained with 
DAPI, which allows for chromosome identification as shown in a reverse DAPI image 
(d). Image (b) shows the FITC-labeled PNA telomeric signals and the PNA centromeric 
signal for chromosome 2 (test image). Frame (c) shows this same metaphase as it appears 
with a PI-stain (reference image). For each chromosome, CGH software transformed the 
intensities of telomere signals into ratio profiles averaged over the 20 (or 30) homologs. 
These ratios were based on the florescence intensities of the test and reference images. As 
seen in (e), telomeres of chromosome X, as identified by the inverted DAPI banding 
pattern, showed a short arm telomere relative fluorescence unit (RFU) value of 4.25, 
while the long arm telomere value was 5.00. Note that signal intensities between the 
replicate sister chromatids of each homolog were very similar. 
 
 
(a) (b) 
(c) (d) 
(e) 
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Results 
 
Chromosome-specific telomere length assays were performed on lymphocyte 
samples obtained from 24 individuals with mosaicism for trisomy 21, including 12 males 
and 12 females. These study participants ranged in age from 3 weeks old to 28 years old, 
with a median age of 3.5 years old. The age, gender and percentage of trisomy 21 cells 
for each proband are given in Table 6. The distribution of the percentage of trisomic cells 
and the age of all study subjects are shown in Figure 10.   
 
Overall telomere length in euploid and trisomic cells 
Estimates of the overall telomere intensity in each individual were obtained by 
averaging the intensity values of all chromosomes, except chromosome Y (which was 
excluded from the analysis since the females would not have a correlate chromosome). 
This analysis showed no significant correlation between overall telomere intensity values 
and the percentage of trisomic cells, which was log transformed values present in the 
probands (Pearson correlation, r = -0.15, p-value = 0.485). In addition, no correlation 
between overall telomere intensity values and age was observed in the study cohort, 
which was comprised of predominantly young individuals (Pearson correlation, r = -
0.117, p-value = 0.587) as shown in Figure 11a and 11b. 
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Table 6: Age, gender and percentage of trisomy 21 cells of 24 study subjects 
 
 
 
Case Age Gender Percentage of trisomy 21 cells 
1 0.4 F 24.9 
2 4.0 F 19.0 
3 0.1 M 50.5 
4 12.0 F 26.5 
5 3.0 M 23.8 
6 0.3 M 48.0 
7 2.0 F 9.4 
8 28.0 F 90.5 
9 5.0 M 12.0 
10 25.0 M 8.4 
11 14.0 F 10.3 
12 7.0 F 91.6 
13 3.0 M 29.5 
14 11.0 F 17.6 
15 0.9 M 62.0 
16 4.0 M 10.8 
17 0.3 F 56.8 
18 0.5 M 10.9 
19 11.0 M 6.55 
20 21.0 F 92.7 
21 2.5 F 43.0 
22 3.0 F 23.2 
23 18.0 M 11.0 
24 2.9 M 11.7 
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Figure 10: Distribution of the percentage of cells having trisomy 21 and age for the 
24 study subjects. Note the skewing of distribution of trisomic cells toward low levels 
(less than 20%) (a), and the skewing of the study participants’ age toward very young 
individuals (less than 5 year old) (b). 
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To test the primary hypothesis of this study, the overall telomere intensity values 
between euploid and trisomic cells “within a person” were compared. Telomere 
intensities for the short arm of the 23 different chromosomes (1-22 and X) in females and 
24 different chromosomes (1-22, X and Y) in males were compared between the two cell 
types using a paired t-test. Analyses were performed in the same manner for long arm of 
the chromosome. A Bonferroni correction for multiple comparisons was applied for these 
tests [the p-value was set at < 0.001 (i.e., 0.05/46 and 0.05/48)]. The mean, standard 
deviation, mean of the differences and p-values for these individual-specific comparisons 
are summarized in Table 7. A significant difference between telomere intensity values 
present in euploid compared to trisomic cells was observed for 7 individuals for the short 
arms of chromosomes and in 13 individuals for the long arms of chromosomes. A total of 
7 individuals had significantly different values for both their short arms and long arms. 
For each of these cases, there was consistency in the directionality of the observed 
differences (i.e., shorter in the trisomic cells for both long arm/short arm or longer in the 
trisomic cells for both long arm/short arms). No clear ascertainment pattern was observed 
for the probands who had shorter telomeres in their trisomic cells versus those who had 
longer telomeres in their trisomic cells (not apparently related to age or the proportion of 
trisomic cells).    
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Figure 11: Overall mean telomere intensity compared to (a) the probands’ 
percentage of cells with trisomy 21 and (b) the proband’s age. Each data point 
represents an individual (○). No significant correlation was observed for the trisomic 
percentage (Pearson correlation, r = -0.15, p-value = 0.485) or age (Pearson correlation, r 
= -0.117, p-value = 0.587). 
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Table 7: Telomere intensity values in euploid compared to trisomic cells obtained from lymphocytes of individuals having mosaicism for 
trisomy 21. 
Age 
(years) 
Short arm Long arm 
Euploid cells Trisomy 21 cells Mean of the differences 
(e-t ) 
p-value 
Euploid cells Trisomy 21 cells Mean of the difference 
(e-t) 
p-value 
Mean SD Mean SD Mean SD Mean SD 
0.1 2.883 0.544 3.188 0.809 -0.305 0.027 2.789 0.416 2.933 0.548 -0.144 0.095 
0.3 2.780 0.519 2.223 0.361 0.556 <0.0005 2.568 0.502 2.148 0.405 0.420 <0.0005 
0.3 4.916 1.149 4.349 1.068 0.568 0.006 4.526 1.097 4.013 0.939 0.513 0.003 
0.4 3.630 0.846 3.851 0.937 -0.221 0.137 3.707 0.883 3.397 0.774 0.311 0.957 
0.5 4.883 1.287 4.589 1.147 0.294 0.092 4.443 0.860 4.551 0.923 -0.108 0.490 
0.9 4.206 1.015 3.883 1.004 0.322 0.027 4.008 0.816 3.610 0.838 0.399 0.004 
2.0 2.848 0.792 3.376 0.829 -0.529 <0.0005 2.469 0.495 3.152 0.745 -0.683 <0.0005 
2.5 2.774 0.544 2.100 0.647 0.674 <0.0005 2.489 0.419 1.739 0.237 0.750 <0.0005 
2.9 4.297 1.019 4.485 0.979 -0.189 0.078 3.993 0.740 3.954 1 0.009 0.956 
3.0 2.000 0.352 2.155 0.277 -0.154 0.017 2.021 0.272 2.249 0.392 -0.228 0.0004 
3.0 6.587 1.374 5.856 1.397 0.731 0.058 6.166 1.379 5.608 1.256 0.558 0.076 
3.0 3.559 0.504 2.666 0.482 0.892 <0.0005 3.227 0.556 2.606 0.568 0.622 <0.0005 
4.0 2.917 0.443 2.580 0.412 0.337 0.001 2.857 0.369 2.472 0.361 0.385 <0.0005 
4.0 3.157 0.733 2.764 0.472 0.394 0.006 3.229 0.705 2.565 0.435 0.664 <0.0005 
5.0 4.256 1.009 4.485 0.979 -0.228 0.034 3.956 0.733 3.984 1 -0.0282 0.870 
7.0 2.363 0.586 2.917 0.523 -0.554 <0.0005 2.291 0.389 2.678 0.387 -0.389 <0.0005 
11.0 3.426 0.811 2.737 0.681 0.690 <0.0005 3.296 0.688 2.581 0.550 0.716 <0.0005 
11.0 2.533 0.527 2.879 0.741 -0.345 0.001 2.410 0.592 2.844 0.832 -0.434 0.036 
12.0 2.759 0.432 3.575 0.597 -0.816 <0.0005 2.646 0.490 3.415 0.497 -0.769 <0.0005 
14.0 2.295 0.589 2.197 0.337 0.098 0.249 2.019 0.352 2.090 0.390 -0.070 0.332 
18.0 2.948 0.750 3.360 1.819 -0.412 0.052 2.575 0.492 2.942 0.625 -0.368 0.0004 
21.0 2.819 0.621 3.166 0.702 -0.347 0.029 2.779 0.740 2.983 0.493 -0.204 0.210 
25.0 2.887 0.909 2.795 0.568 0.091 0.606 2.577 0.524 2.846 0.614 -0.269 0.0003 
28.0 2.266 0.412 2.730 0.565 -0.464 0.001 2.102 0.324 2.552 0.488 -0.450 <0.0005 
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Chromosome-specific differences in telomere length 
 The telomere intensity values of each of the autosomal and sex chromosomal arms of all 
individuals (n = 24 for chromosomes 1-22 and X; n = 12 for chromosome Y) were visualized 
using boxplots of the raw data for euploid and trisomic cells (Figure 12). In this figure, telomere 
intensities were not equal among all chromosome arms. The shortest telomeres were found on 9q 
for both trisomic and euploid cells, with 1p, 2q, 4p, 16q, 17p, 17q, 19p and 22q also tending to 
have relatively short telomeres.  The longest telomeres were found on 3p for both trisomic and 
euploid cells, with the Y chromosome also tending to have longer telomeres in the males 
evaluated. 
 
A striking similarity of the telomere length profiles of the euploid and trisomic cells was 
also observed (Figure 13a). The difference in telomeric values in the euploid compared to 
trisomic cells resulted in positive values (shorter in trisomic cells) for 26 chromosomal arms and 
negative values (longer in trisomic cells) for 21 chromosomal arms (Figure 13b). However, the 
majority of these values were not significant using a paired t-test, except for the difference for 
2q, and 6q (Table 8). However, if one applies a Bonferroni correction for multiple tests (48 
tests); none of the observed difference values reach statistical significance. 
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Figure 12: Boxplot distribution of chromosome-specific telomere lengths in euploid and trisomic cells of all study 
subjects (n=24). The data for the individual chromosomes in euploid cells (light blue = short arm, pink= long arm) and 
trisomic cells (dark blue =short arm, red = long arm) is shown by the minimum (lower bar), 25
th
 percentile (lower box 
boundary), median (line), 75
th
 percentile (upper box boundary) and maximum (upper bar). 
 
 
1p       2p          3p         4p        5p        6p        7p        8p         9p       10p       11p      12p      13p      14p       15p     16p       17p      18p      19p      20p      21p       22p       Xp       Yp 
 1p       2p          3p         4p        5p        6p        7p        8p         9p       10p       11p      12p      13p      14p       15p     16p       17p      18p      19p      20p      21p       22p       Xp       Yp 
 1q         2q         3q        4q        5q        6q        7q        8q         9q       10q       11q      12q      13q      14q      15q       16q      17q      18q     19q       20q        21q      22q      Xq      Yq 
1p      2p      3p       4p       5p      6p      7p        8p      9p     10p     11p     12p     13p    14p    15p     16p     17p     18p    19p     20p      21p    22p     Xp     Yp 
1q       2q       3q       4q       5q       6q       7q       8q       9q      10q     11q      12q     13q     14q     15q    16q      17q     18q     19q     20q     21q     22q      Xq      Yq 
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Figure 13: Mean telomere lengths in euploid and trisomic cells of all study subjects (n=24). (a) The data from individual 
chromosome arms in euploid cells (gray) and trisomic cells (black) reveal a nearly parallel course for all chromosomes. (b) The 
difference (euploid-trisomic) in telomere intensity values are shown for each chromosome. 
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Table 8: Chromosome-specific telomere lengths in euploid and trisomy 21 cells obtained from lymphocytes of individuals with mosaicism for 
Down syndrome (n=24)
Chromosome 
Short arm Long arm 
Eup cells Tri21cells Mean difference (e-t) 
 
p-value  Eup cells Tri 21 cells Mean difference (e-t) 
 
p-value 
Mean SD Mean SD Mean SD Mean SD 
1 2.381 0.471 2.314 0.431 0.067 0.532 3.554 0.7250 3.657 0.687 -0.103 0.562 
2 3.474 0.682 3.405 0.838 0.068 0.683 2.392 0.376 2.160 0.463 0.231 0.044 
3 4.300 0.899 4.391 0.920 -0.090 0.635 3.463 0.685 3.303 0.623 0.160 0.327 
4 2.471 0.380 2.593 0.423 -0.122 0.317 3.753 0.649 3.767 0.736 -0.013 0.935 
5 3.166 0.589 2.972 0.579 0.194 0.197 3.081 0.485 3.006 0.506 0.074 0.538 
6 3.448 0.553 3.658 0.802 -0.211 0.181 3.518 0.707 3.220 0.641 0.299 0.049 
7 2.885 0.359 2.760 0.569 0.125 0.238 3.331 0.615 3.132 0.512 0.199 0.232 
8 3.418 0.554 3.608 0.733 -0.190 0.198 2.798 0.499 2.672 0.556 0.126 0.282 
9 4.051 0.697 3.868 0.669 0.183 0.285 2.303 0.444 2.214 0.413 0.090 0.310 
10 3.585 0.572 3.698 0.792 -0.113 0.441 2.856 0.512 2.845 0.590 0.011 0.931 
11 2.855 0.472 2.843 0.489 0.012 0.912 3.454 0.669 3.685 0.814 -0.231 0.172 
12 3.146 0.636 3.081 0.633 0.065 0.702 2.988 0.509 3.031 0.528 -0.043 0.752 
13 3.371 0.615 3.458 0.821 -0.087 0.574 3.467 0.619 3.509 0.859 -0.041 0.818 
14 3.233 0.741 3.284 0.782 -0.050 0.769 3.057 0.500 2.972 0.589 0.085 0.568 
15 3.242 0.964 3.166 0.603 0.075 0.743 3.469 0.659 3.550 0.773 -0.081 0.699 
16 2.621 0.471 2.568 0.457 0.053 0.628 2.562 0.462 2.628 0.519 -0.066 0.578 
17 2.806 0.651 2.748 0.611 0.057 0.738 2.612 0.396 2.547 0.565 0.064 0.611 
18 3.810 0.684 3.691 0.799 0.120 0.503 3.768 0.579 3.785 0.745 -0.017 0.923 
19 2.513 0.441 2.550 0.555 -0.036 0.784 2.988 0.483 3.293 0.991 -0.304 0.188 
20 3.313 0.480 3.283 0.667 0.030 0.861 2.704 0.311 2.672 0.470 0.032 0.770 
21 3.655 0.829 3.816 1.240 -0.161 0.548 3.012 0.553 2.950 0.649 0.063 0.718 
22 3.851 1.306 3.660 1.120 0.191 0.465 2.490 0.430 2.560 0.517 -0.070 0.475 
X 3.600 0.851 3.420 0.681 0.180 0.352 3.277 0.705 3.281 0.844 -0.005 0.982 
Y 4.269 0.473 4.520 1.345 -0.251 0.470 3.387 0.710 3.758 0.737 -0.371 0.124 
 85 
 
Discussion 
 
Telomere shortening has been previously observed in older individuals with 
Down syndrome, compared to normal age-matched controls, using terminal restriction 
fragment (TRF) methodology (Vaziri et al., 1993). The TRF assay is one of the first 
techniques used to assess telomere length. Based on the fact that that telomeres lack 
cleavage sites for restriction enzymes, the TRF assay is implemented by cutting 
genomic DNA using a common 4 base-cutter restriction enzyme, followed by gel 
electrophoresis and hybridization to a probe with telomere specific sequence, to 
obtain an average (pooled over all chromosomes) telomere length based on the size 
parameters of the resulting DNA smear. However, if a subset of chromosomes has 
short telomeres, or possibly have elongated telomeres, this information could be 
missed using the TRF assay. Therefore, in this study, we elected to investigate the 
length of telomere repeats using a chromosome-specific assay. Also, by studying 
individual chromosome arms in people who have mosaicism for trisomy 21, we were 
able to measure telomere lengths in normal and trisomic cells obtained from the same 
individual, thereby controlling for the potentially confounding effects of heritable 
variation in telomere lengths and different environmental exposures between people.  
 
This is the first study to use quantitative FISH methodology to measure 
chromosome-specific telomere length profiles of trisomic and euploid cells. However, 
this chromosome-specific assay has been previously shown to be a reliable measure of 
telomere length in studies completed on a variety of cell types from different 
individuals (Lansdorp et al., 1996; Martens et al., 1998; Graakjaer et al., 2003). 
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Specifically, we have shown that the overall average of telomere length estimates 
obtained from our adaptation of the quantitative FISH assay correlate with the 
estimates obtained from the “gold standard” TRF assay (Leach et al., 2004).  
 
Of twenty-four subjects evaluated in this current study, we observed a weak 
negative correlation between telomere intensity values and the percentage of trisomic 
cells present in the probands. However, our observation failed to show a significant 
correlation between percentage of trisomy 21 cell and telomere length. This 
observation could be attributable to the small sample size. In addition, given that the 
individuals with mosaicism who were evaluated in this project had a skewing of their 
distribution of trisomic cells toward low levels  (less than 20%), as shown in Figure 
10a,  it is difficult to conclude that dosage of trisomy 21 cells has no impact on 
telomere length.  The lack of a clear effect of the proportion of trisomic cells on 
telomere length could reflect the low percentage of trisomic cells in these individuals, 
who also showed fewer other phenotypic traits seen in people with Down syndrome, 
suggesting they had a lower “threshold” of imbalance.  
 
 We also observed a weak, non-significant negative correlation between 
telomere intensity and age. However, the skewing of the study participants’ age 
toward very young individuals (less than 5 year old) is a possible explanation for this 
observation. Therefore, since most of study subjects were very young, we cannot 
conclude that in general, age has no effect on telomere length in individuals with 
mosaicism for Down syndrome. However, this study is the first to show that the 
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presence of a trisomic complement in young individuals has a minimal impact on 
telomere length. 
 
While no generalized effect of trisomy 21 was observed, differences in overall 
telomere intensity between euploid and trisomic cells “within a person” were detected 
for a subset of people. Approximately 50% of all individuals studied had telomere 
intensity values in euploid cells that were brighter than those in the trisomic cells for 
both arms of their chromosomes. However, significant differences were found in only 
16.7% for short arms and 25% for the long arm. Unexpectedly, the young adults in 
this study (18 to 28 years old) tended to have longer telomeres in their trisomic cells 
longer compared to their euploid cells.  
 
These observations suggest that the telomere length dynamics in young 
individuals having low levels of trisomic cells are not clearly different from those of 
young people having normal chromosomal complements, the latter of whom have 
been shown to have the greatest decrease in their telomere length during the first years 
of life, with little additional attrition occurring until they reach middle age (Zeichner 
et al., 1999). 
 
We found that telomere lengths were not equally distributed among all 
chromosome arms. We also observed that while each person has his/her own specific 
telomere length profile; there was a common profile of telomere length shared 
between different individuals. This observation is also consistent with results of 
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previous reports in people with normal chromosomal complements (Graakjaer et al, 
2003, Mayer et al., 2006).  
 
The finding that both trisomic and euploid cells had strikingly similar 
chromosome-specific telomere length profiles (Table 8 and Figure 13a) implies that: 
(1) dosage of trisomy 21 cells has a minimal impact on telomere lengths in this young 
population; and (2) the impact, if any, tends to be generalized for all chromosomes.  
  
In summary, the results of this study failed to detect a clear influence of a 
trisomy 21 complement in telomere length in young children and young adults. 
However, this conclusion does not seem to apply to older people having trisomy 21. 
Telomeres in euploid and trisomic cells may be subjected to different regulatory 
control processes and such processes may be acquired later in life. In addition, 
sensitivities to mutations that are accumulated over time, which could result in 
different in telomere attrition rates, may be different between euploid and trisomic 
cells. Furthermore, the cell cycle in people having trisomy 21 has been shown to be 
shorter than that of normal people (Leonard and Merz, 1983). Given this observation, 
it is feasible that the telomeric attrition observed in older individuals having Down 
syndrome simply reflects the fact that their cells have completed more rounds of 
replication. The shortening of the cell cycle may also explain, at least in part, the 
premature aging phenotype associated with Down syndrome since trisomic 
individuals complete more cell cycles in a smaller amount of time. Clearly, additional 
studies should be carried out in extended populations with individuals from older 
ages. In addition, it would be very interesting to perform a longitudinal study in this 
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young population, to measure their rate of telomere shortening in trisomic and euploid 
cells compared to that of age-matched controls having a normal complement. 
Collectively, further studies of telomere length variation in people having mosaicism 
could provide insight about the association between telomere attrition and the 
premature aging phenotype in Down syndrome.   
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Chapter 4 
 
Frequency of chromosomal instability and chromosome-specific telomere length 
profiles in individuals with mosaicism for Down syndrome 
 
Introduction 
 
Acquired chromosomal changes have been associated with the development of 
several diseases including, but not limited to, solid tumors [such as malignant glioma 
(Lindström et al., 1991), prostate cancer (Zitzelsberger et al., 1994), renal cell 
carcinoma (Kuroda et al., 2010), malignant melanoma (Balaban et al., 1986)]; 
hematological disorders [such as leukemia and lymphoma (Kaneko et al.,1982, Clare 
et al., 1982, Hagemeijer et al., 1981; Wisniewski and Hirschhorn,1983)]; and 
neurological disorders [such as Alzheimer disease (Migliore et al., 1997; Petrozzi et 
al., 2002; Zekanowski and Wojda, 2009) and Parkinson disease (Petrozzi et al., 2002; 
Migliore et al., 2002; reviewed in Migliore et al., 2011)]. Several investigators have 
shown the frequencies of acquired chromosomal abnormalities involving the sex 
chromosomes to be increased in cultured lymphocytes from healthy older individuals 
(Jacobs et al, 1961; Jacob et al., 1963; Fitzgerald and McEwan, 1977; Martin et al, 
1980; Guttenbach et al, 1995; Richard et al, 1994; Catalan et al, 2000), but there is a 
paucity of information available regarding the frequency of acquired autosomal 
abnormalities and their clinical consequences. Furthermore, while sex chromosome 
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loss has been clearly shown to be correlated with age (Bolognesi et al., 1999; Bonassi 
et al., 2001), the influence of age on acquired autosomal aneuploidy is not well 
established. Evidence for a relationship between aging and an increased frequency of 
acquired chromosomal instability comes from studies of individuals having premature 
aging syndromes, such as Werner syndrome. Cells from individuals having Werner 
syndrome have shown a higher incidence of chromosomal abnormalities than cells 
from normal controls (Crabbe et al., 2007; Ariyoshi et al., 2007). These studies also 
showed a relationship between telomere dysfunction and acquired chromosome 
abnormalities (Crabbe et al., 2007; Ariyoshi et al., 2007), which is a finding that 
supports the previous hypotheses of Barbara McClintock (McClintock, 1941). Aviv 
and Aviv (1998) proposed that erosion of the telomere leads to genomic instability. At 
the chromosomal level, the resultant abnormalities may give rise to chromosome 
fragments lacking a centromere (acentric fragments), which would subsequently not 
be pulled toward the daughter nuclei at the time of nuclear division and would either 
randomly segregate to the nuclei of daughter cells or be excluded into a small 
cytological structure called a micronucleus/micronuclei (MN).  
 
It is well documented  that people with Down syndrome age prematurely, as 
they show signs of degenerative changes in their physical appearance, including 
premature graying and loss of hair, age-related visual and hearing loss, skin atrophy 
and neuropathologic features identical to those observed in people having Alzheimer 
disease (Potter, 1991; Esbensen, 2010). However, little is known about the frequency 
of acquired chromosome abnormalities in people having Down syndrome. 
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In addition to the standard G-band karyotyping, the cytokinesis-blocked 
micronucleus (CBMN) assay is one of the preferred methods for assessing acquired 
DNA damage at the chromosome level (Fenech et al., 2003). It allows for the 
measurement of acquired whole chromosomal loss and/or chromosomal structural 
abnormalities (i.e., acentric fragments; dicentrics, etc.), with the aberrant chromatin 
being excluded into MN. Different mechanisms may be involved in the formation of 
MN, including (but not limited to): 1) misrepaired or unrepaired DNA double-strand 
breaks resulting in acentric chromosome fragments; 2) hypomethylation of 
centromeric and pericentromeric repeat sequences leading to malsegregation of 
chromosomes and subsequent loss; and 3) mutations leading to defects in 
kinetochores or microtubules, defects in mitotic spindle assembly, mitosis check point 
genes; and/or abnormal centrosome amplification. A strong correlation between 
chromosomal aberrations, as assessed using the gold standard of metaphase 
chromosome studies and MN formation has been shown (Ramalho et al., 1988). The 
CBMN assay also allows for measurement of other biological markers which appear 
as distinctive cytological structures, including nuclear buds (NBUD), which are 
thought to be biomarkers of elimination of amplified DNA and/or DNA repair 
complexes, and nucleoplasmic bridges (NPB), which are thought to be biomarkers of 
DNA misrepaired and/or telomere end fusions (Fenech et al., 2011).  
 
NPB are thought to originate primarily from dicentric chromosomes that are 
pulled to opposite poles of the cell during anaphase. In turn, dicentric chromosomes 
are thought to arise from misrepair of chromosome breaks or telomere end fusions. In 
addition, defects in protein complexes involved in sister chromatid separation during 
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anaphase may result in NPB formation. NBUD are thought to occur as a means for 
elimination of amplified DNA, but may also be present as a remnant of NPB breakage 
(Fenech et al., 2011). 
 
MN frequencies have not been extensively studied in individuals with Down 
syndrome (Table 9). Investigators who evaluated buccal cells showed a significant 
increase in MN frequencies in individuals with Down syndrome compared to normal 
healthy controls (Thomas et al., 2008; Ferreira et al., 2009). However, the studies 
completed in lymphocytes were discrepant, with one group of investigators finding a 
decrease in MN frequencies in people having Down syndrome (Scarfi et al., 1990), 
while the other group saw no significant difference in MN frequencies for people with 
Down syndrome compared to age-matched controls (Maluf and Erdtmann, 2001). 
Similar discrepancies have been observed when comparing younger people having 
Down syndrome to older trisomic individuals, with older subjects tending to have a 
higher frequency of spontaneous MN than younger individuals for buccal cells 
(Ferreira et al., 2009), but not lymphocytes. However, MN frequencies in older 
individuals with Down syndrome have been noted to be higher than those observed in 
younger individuals with Down syndrome when their lymphocytes were treated with 
mitomycin-C (MMC), which is a DNA cross-linking agent (Scarfi et al., 1990). In 
addition, individuals with Down syndrome appeared to be more sensitive to MMC, as 
their MMC-induced MN frequency was higher than healthy age-matched controls.
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Table 9: Summary of previous studies assessing MN frequencies in individuals with Down syndrome 
†
range, mean   S.D., *Overall MN frequency in spontaneous and mitomycin-C (MMC)-induced MN, ** approximated percentage from published histograms
Cell type 
Individuals with Down syndrome Normal healthy controls 
Reference Older group Younger group Older group Younger group 
Age†(years) n MN (%) Age†(years) n MN (%) Age†(years) n MN (%) Age†(years) n MN (%) 
Lymphocytes* 37-55, 44.7±3.8 4 0.86±0.1 9-16, 13.0±1.7 3 0.64±0.06 41-54, 45.8±2 6 1.39±0.11 21-33, 27.6±1.5 8 1.02±0.1 Scarfi et al., 1990 
Lymphocytes - - - 0.7±1.8 30 10.17±3.64 - - - 3.5±4.9 30 9.3±3.1 Maluf et al, 2001 
Buccal cells - - - 5-20, 10.4±5.6 21 0.25** 64-75, 67.1±2.6 31 0.14** 18-26, 22.5±2.2 30 0.03** Thomas et al.,2008 
Buccal cells ≥21,30.8±.4 10 1.00** 
 
<10, 5.5±2.6 
<20, 14.1±3.5 
 
10 
10 
 
0.45** 
0.55** 
≥21, 31.6±8.8 10 0.25** 
 
<10, 5.7±3.2 
<20, 13.9±3 
 
10 
10 
 
0.2** 
0.15** 
Ferreira et al., 2009 
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Clearly, there is a lack of consensus regarding the influence, if any, that a trisomy 
21 complement may have on the propensity for a cell to acquire chromosomal instability. 
Furthermore, it is not known if the premature aging present in people with trisomy 21 is 
associated with an increased frequency of acquired chromosomal abnormalities. One 
potential mitigating factor in the interpretation of the previous data is that the observed 
difference in response between people having Down syndrome could reflect differences 
in their genetic make-up (genes involved in check points, DNA repair, etc), as well as 
differences in environmental exposures. Therefore, in this study, we used the CBMN 
assay in combination with interphase FISH technology to determine the frequency of MN 
in isogenic trisomic compared to euploid cells obtained from older individuals who were 
described as having “mosaicism” for trisomy 21. In addition, to determine if the 
chromosomal content of the MN and NBUDs had a non-random pattern, we used 
Spectral Karyotyping (SKY) technology. To the best of our knowledge, this is the first 
study to determine the chromosomal content of MN (using SKY) from the cells of 
individuals having Down syndrome. 
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Materials and Methods 
 
Study Participants 
Lymphoblast cell lines from 8 individuals with mosaic Down syndrome were 
ascertained through collaboration with Dr. Edmund Jenkins, who has amassed a 
collection of lymphoblast cell lines from individuals who were seen through the New 
York State Developmental Disability Service System (Table 10). Upon receipt in our lab, 
the cells were thawed and established in culture for at least one week to ensure that the 
cells demonstrated growth. 
 
Cell Cultures 
Upon the sample arrival, frozen lymphoblast cell lines were quickly warmed to 
37
o
C, washed twice in sterile 1XPBS and established in culture using  a lymphoblast 
media (RPMI 1640) containing 10% FBS and antibiotic (100 U of penicillin and 100 µg 
of streptomycin). Cell cultures were maintained at 37
o
C, in 5% CO2 until they 
demonstrated adequate growth. At that time the cell solutions were sub-cultured to 
encourage log growth of the cells, with the harvest occurring 24 hours following sub-
culture initiation.  Approximately 30 minutes before harvesting, colcemid was added to 
the cultures to enrich the cultures for cells at metaphase. Chromosomes were harvested 
using standard procedures (Moorhead, et al., 1960). 
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CBMN and FISH Assays 
After successful establishment in culture, cytochalasin B (Cyt-B) was added to a 
final concentration of 3µg/ml, 44 hours after sub-culturing. Cyt-B, which inhibits 
cytokinesis by blocking microfilaments, captures cells at the telophase portion of the cell 
cycle, thereby preventing the cytoplasm from dividing and causing the resultant cell to 
appear binucleated. Twenty-eight hours after the addition of Cyt-B, lymphoblast cultures 
were harvested as described previously (Leach and Jackson-Cook, 2001). Cell pellets 
were dropped onto slides. The slides were then placed on a hot plate at 60C for 1 hour, 
followed by aging at room temperature for 4 days. FISH was performed using probes 
specific for chromosome 21 (test probe) and chromosome 13 (control probe). The test 
probe used was one that is localized to 21q22.13-21q22.2 
(D21S259\D21S341\D21S1432) (Abbott, IL). The control probe was specific for band 
13q14 (RB1 locus) (Abbott, IL) and served as an internal control for hybridization 
efficiency. These probes were hybridized onto cytokinesis-blocked cells to determine 
their trisomic versus euploid status. Briefly, prior to hybridization the slides were 
dehydrated in a cold ethanol (series of 70%, 85% and 100% ethanol). Following 
dehydration, the slides were air-dried. A total of 10μl of the 13/21 probe mixture was 
added to appropriate hybridization areas on the slides. The target chromatin and probes 
were then co-denatured at 73°C for 2 minutes and hybridized in a pre-warmed, 
humidified chamber at 37ºC for 4-16 hours. Upon completion of hybridization, the excess 
and non-specifically bound probes were removed by washing (0.4X SSC/0.3%NP-40 
solution at 72°C for 2 minutes, followed by 2X SSC/0.1% NP-40 wash solution for 1 
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minute). The chromatin in the binucleates was visualized by staining with a 
DAPI/antifade solution (Abbort, IL). Probe signals were visualized using a Zeiss Axiskop 
equipped with single (spectrum Orange, Spectrum Green) and triple band pass filters. For 
each individual, a total of 1000 cells were randomly scored to determine the percentage 
of trisomic cells present. In addition, a total of 500 binucleated cells were randomly 
scored for frequencies of MN, NPB and NBUD in trisomy 21 compared to euploid cells. 
The criteria for recognition of binucleated cells, MN, NPB and NBUD followed the 
guidelines by Fenech, et al. (2003). Representative images were documented using a 
Cytovision Imaging system from Applied Imaging. 
 
SKY analysis of micronuclei 
Slides were aged at room temperature for 4 days prior to the SKY experiment. 
SKY was performed according to the manufacturer’s protocol (Applied Spectral Imaging, 
CA) as adapted by Leach and Jackson-Cook (2001). Briefly, slides were denatured in a 
70% formamide/2XSSC solution (pH 7.0) at 73˚C for 2 minutes. Following denaturation, 
the slides were briefly rinsed in cold water and then dehydrated in an ethanol series (70%, 
85% and 100% for 2 minutes each at room temperature). The SKY probe (Applied 
Spectral Imaging, CA) was denatured at 75˚C for 10 minutes and suppression hybridized 
at 37˚C for 60 minutes to bind repetitive sequences. After suppression hybridization, the 
denatured probe was added to the denatured slides, hybridizion occurring in a humidified 
chamber and at 37˚C for approximately 44 hours. At the completion of hybridization, the 
excess and non-specifically bound probe was removed by washing (using a 
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0.4xSSC/0.3%NP-40 solution at 73˚C for 2 minutes, followed by a one minute wash at 
room temperature in a 2xSSC/0.1%NP-40). Indirectly labeled probes (biotin and 
digoxigenin) were detected using buffers with avidin-Cy5, mouse anti-digoxin and goat 
anti-mouse conjugated to Cy5.5 (provided by manufacturer). All incubations were for 40 
minutes at 37˚C. The binucleates were counterstained with DAPI/antifade (Applied 
Spectral Imaging, CA) to allow for their visualization. A total of 100 MN and their 
contiguous interphase nuclei were identified per study subject using a Zeiss Axioskop 
equipped with a DAPI filter and a custom triple-band pass filter (Chroma, VT). Each MN 
(with adjacent interphase cells) was captured with a SpectraCube system (Applied 
Spectral Imaging, CA). The images were processed using the vendor supplied software 
(Applied Spectral Imaging, CA), which classifies the information obtained by using an 
algorithm that assigns a spectra-specific pseudocolor to all pixels in the image.  
 
Chromosome-Specific Telomere Length Assay 
Slides were aged (either at room temperature for 1-2 weeks or by soaking in 
2xSSC for 10 minutes) prior to the FISH experiment. Metaphase chromosomes were 
hybridized with a telomere-specific FITC-labeled PNA probe following the 
manufacturer’s protocol (DakoCytomation, Denmark). In addition, an FITC-labeled 
probe that is specific for the pericentromeric region of chromosome 2 was simultaneously 
hybridized to the metaphase spreads as a control (and to serve for standardization of 
intensity values from cell to cell) (Mayer et al., 2006). Briefly, slides were fixed in cold 
Carnoy’s fixative for 1 hour. After air-drying, the slides were rinsed with 1XTBS (Tris-
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Buffered Saline, pH 7.5) for 2 minutes, fixed in 3.7% formaldehyde in 1XTBS for 2 
minutes,  and then rinsed (twice in 1XTBS for 5 minutes). The slides were then treated in 
pre-treatment solution, containing proteinase K, for 10 minutes, rinsed (twice in 1xTBS 
for 5 minutes) and dehydrated (using a cold ethanol series [70%, 85% and 100%]). After 
air-drying, the  a cocktail probe mixture (11µl of FITC-labeled telomere specific probe 
and 1 µl of FITC-labeled centromere-2 probe  per subject [a half slide area]) was added 
to each slide and the probe and metaphase spreads co-denatured in a thermocycler at 
80°C for 3 minutes. After hybridization in a dry hybridization chamber at room 
temperature for 2 hours, the excess and unbound probes were removed by rinsing (once 
in manufacturer provided rinse solution at room temperature for 1 minute, followed by 5 
minutes in a manufacturer provided wash solution at 65°C).  Following serial dehydration 
in a cold ethanol series (70%, 85% and 100%), the slides were air-dried, and then 
counterstained with a 5:1 DAPI/propidium iodide solution. 
 
The telomere lengths of each chromosome were assessed using a semi-
quantitative FISH method (CGH software from Applied Imaging Cytovision System) as 
described by Leach et al., (2004). Briefly, three images were captured with a CCD 
camera for each metaphase: (1) a reverse DAPI image, which allows for chromosome 
identification and subsequent karyotyping; (2) a test/ FITC image, showing telomeric and 
centromeric probe signals; and (3) a reference/ propidium iodide image. Fluorescent 
intensities obtained from the “test” and “reference” images were used for calculating the 
ratio profiles of relative telomere intensity for each chromosome arm. Overlapping 
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telomeres or telomeres that were in close proximity were excluded from the analysis. For 
each person the intensity values were averaged over 20 homologs from 10 euploid cells, 
and 20 homologs (30 homologs for chromosome 21) from trisomic cells. 
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Results 
 
 Analyses were completed on lymphoblast samples obtained from 8 individuals 
who were previously categorized (by Jenkins, et al) as having two cell lines (acquired 
mosaicism for trisomy 21 for 5 cases and constitutional mosaicism for 3 cases), as 
summarized in Table 10. Prior to our analyses, the percentages of trisomy 21 cells from 
all lymphoblast cultures were re-evaluated. A total of 5 individuals had trisomic cells 
predominate, while 2 individuals had euploid cells predominate in the current cultures. 
Therefore, chromosomal instability frequencies and telomere length values could be 
analyzed in either trisomic or euploid cells from these individuals, respectively, but not 
both as was initially planned. For one individual both trisomic (10.7%) and euploid 
(89.3%) cells were present. 
 
Cellular distribution of chromosome 21 and 13 probe signals 
The proportion of binucleated cells having MN, NPB, NBUD (Figure 14), as well 
as the total frequency of cytome assay aberrations (MN + NPB + NBUD) was determined 
for each case, along with information regarding their dementia status (Table 10). The 
results of the FISH scoring were used to categorize the binucleates (with or without 
cytome aberrations) into cells having or lacking signals for chromosomes 21 and/or 13. 
These categorizations included cells having numerical abnormalities (i.e., hyperdiploidy 
and hypodiploidy) and unequal segregation (i.e., nondisjunction) of the chromosomes 21 
and 13 into the daughter nuclei and/or cytological structures as summarized in Table 11. 
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Hyperdiploidy of chromosome 21and/or 13 was found to be the most frequent cellular 
alteration. Chromosome 21 and 13 were not frequently excluded in MN. Of the 430 
binucleates scored that had MN, only 11 (2.56%) contained signals having chromatin 
from the region targeted by the probe for chromosome 21, with only 10 MN (2.33%) 
having a signal for the chromosome 13 probe. From these binucleates, “corrective” cells, 
which showed the exclusion of chromosome 21 or 13 into MN (possible trisomy rescue) 
resulting in a balanced complement for the binucleates, were not frequently seen. The 
ratio of the corrective cells to non-corrective cells, the latter of which contained an 
imbalance of chromosome 21 or 13 (either hyperdiploidy or hypodiploidy) was 1 to 2.67 
and 1 to 9 for chromosomes 21 and 13, respectively. Interestingly, 98 of the 430 cells that 
contained MN (23%) had numerical aberrations for chromosomes 13 and/or 21 that were 
not included in the MN. In comparison, only 115 of the 3,536 binucleates without MN 
(3.3%) had acquired numerical aberrations involving chromosomes 13 and/or 21. 
Therefore, even though the cytome aberrations did not reflect all chromosomal anomalies 
that were present in the cells, the observation of a MN (or other cytome structures) was a 
good indicator that the parent cell had chromosomal instability. 
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Table 10: Frequencies of MN, NBUD and NPB observed from CBMN and FISH assays and overall telomere length obtained from 8 individuals 
with mosaicism for Down syndrome, according to their age, gender and dementia status. 
 
MCI = mild cognitive impairment, Tri21= trisomy 21cells, Eup = euploid cells, RFU = relative fluorescent unit, *Total cytome abnormalities determined by the sum of 
MN, NBUD and NPB
Case 
Age at 
sample 
collection 
(years) 
Gender 
% Tri21 
Dementia Status 
% MN % NBUD and NPB 
% Total Cytome 
Abnormalities* 
Mean telomere 
intensity value 
Ascertainment 
Current 
cultures 
Tri 21 Eup Tri 21 Eup Tri 21 Eup Tri 21 Eup 
25 47.7 M 96.0 97.1 No 11.4 
(57/500) 
 1.0 
(5/500) 
 12.4 
(62/500) 
 1.97  
26 57.8 M 92.0 93.4 No 8.4 
(42/500) 
 0.4 
(2/500) 
 8.8 
(44/500) 
 2.30  
27 55.1 F 94.0 98.0 No 7.4 
(37/500) 
 2.2 
(11/500) 
 9.6 
(48/500) 
 1.79  
28 60.4 M 92.0 97.8 No  dementia 
(at age 63) 
13.4 
(67/500) 
 0.6 
(3/500) 
 14.0 
(70/500) 
 1.77  
29 78.1 F 90.0 94.6 Yes 14.0 
(70/500) 
 0.6 
(3/500) 
 14.6 
(73/500) 
 1.59  
30 48.6 M 78.0 1.0 No  7.6 
(38/500) 
 0.6 
(3/500) 
 8.2 
(41/500) 
 2.63 
31 57 F 16.0 1.2 MCI  dementia 
(at age 59) 
 13.2 
(66/500) 
 1.0 
(5/500) 
 14.2 
(71/500) 
 1.37 
32 43.1 F 32 10.7 No 34.0 
(17/50) 
8.0 
(36/450) 
 0.67 
(3/450) 
34.0 
(17/50) 
8.7 
(39/450) 
2.96 3.32 
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Figure 14: Representative images of cytological structures observed in binucleated cells following CBMN and FISH 
assays using probes specific for chromosome 21 (red) and chromosome 13 (green). (a) A binucleated cell with a trisomy 
21 complement that had a MN containing a signal for chromosome 21, suggesting a “trisomy rescue” corrective event occurred 
in the right binucleate to give rise to a euploid cell; (b) a binucleated cell with a trisomy 21 complement that had nuclear buds 
containing chromatin from chromosome 21, suggesting that a corrective event (trisomy corrected to euploid complement) 
occurred for both daughter cells; and (c) a trisomy 21 binucleated cell with a NPB that does not contain chromatin for the 
targeted regions evaluated with these probes.
(a) 
 
(b) (c) 
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Table 11: Segregation of chromosomes 21 and 13 into MN and acquired aneuploidy for chromosomes 21 and 13 in binucleates lacking cytome 
abnormalities 
Case 
BN with MN BN without MN 
MN with 21 MN with 13 MN without 21 or 13 
NL NDJ21 NDJ13 NDJ21,13 Hypo Hyper Multiple 
C NC C NC Typical NDJ21 NDJ13 NDJ21,13 Hypo Hyper Multiple 
25 0 2 0 0 43 0 0 1 5 5 1 421 4 2 0 4 6 1 
26 0 0 0 0 20 5 1 3 2 8 3 440 1 1 0 6 8 0 
27 0 1 0 2 30 0 0 0 0 3 1 426 1 1 1 2 20 1 
28 1 1 1 2 40 1 1 1 7 12 0 419 1 2 0 2 6 0 
29 0 0 0 0 57 1 0 0 1 11 0 404 2 1 0 8 11 1 
30 0 0 0 0 33 1 0 0 1 2 1 446 1 0 0 3 8 1 
31 1 3 0 1 52 2 1 2 0 3 1 423 0 0 0 0 6 0 
32 1 1 0 4 36 0 1 1 2 6 1 441 0 2 0 0 1 0 
Total 3 8 1 9 311 10 4 8 18 50 8 3421 10 9 1 25 66 4 
      
C = Corrective, NC = Non-corrective, NDJ = Nondisjunction, Hypo = Hypodiploidy, Hyper = Hyperdiploidy, Multiple = Hypodiploidy and hyperdiploidy 
MN with 21 
corrective 
MN with 21 
hyperdiploidy 
MN with 21 
hypodiploidy 
MN without 21 
typical 
MN without 21 
with NDJ 21 
MN without 21 
hypodiploidy 
MN without 21 
hyperdiploidy 
MN without 21 
with NDJ 21, 13 
MN without 21 
multiple 
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Telomere length and correlations of telomere length with the frequency of MN, 
NBUD and NPB   
Figure 15 shows representative images of metaphase chromosomes from an 
individual without dementia and an individual with dementia and illustrates the overall 
trend that was observed for telomeres having less intensity (shorter) in individuals with 
dementia as compared to individuals without dementia.  
 
For these analyses, the individuals studied were categorized into 2 groups: non-
demented (n = 5) and demented (n = 3), regardless of their cell types. Age ranges were 
43.1-57.8 years old (median = 48.6) and 57-78.1 (median=60.4) for non-demented and 
demented groups, respectively. The frequency of cytome abnormalities (MN, NBUD, and 
NPB), as well as the overall telomere lengths are shown in Figure 16a and 16b, 
respectively. To compare the frequency of cytome abnormalities and the overall telomere 
length between the non-demented and demented group, the Mann-Whitney U test was 
applied. This statistic involves ranking all the observations, from the smallest to the 
largest values regardless the dementia status. A U statistic was then calculated using the 
following formula: 
U = R - n (n+1), where n = sample size and R = sum of the rank 
This test was performed using the R statistical software program. We found that 
individuals who had dementia had a significantly higher frequency of cytome 
abnormalities (10.0±1.7% vs 14.3±0.3%, p-value = 0.036, Mann-Whitney U test). A 
regression analysis showed that the observed increased frequency of cytome 
2 
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abnormalities significantly co-varied with age (p-value = 0.003), but age effects alone 
were not attributable for the observed cytome frequency differences (p-value = 0.59). 
Telomere intensity scores between cells from individuals with and without dementia were 
also compared. The telomere intensity values of the cells from people with dementia were 
significantly lower than those observed in cells from people without dementia (1.58±0.20 
vs 2.37±0.54; p-value =0.036, Mann-Whitney U test). A regression analysis showed a 
significance co-variance of dementia status and age on telomere intensity values (p-value 
= 0.04), but neither attribute independently accounted for a significant portion of the 
observed variation (age, p-value = 0.5; dementia, p-value = 0.4). We also observed a 
significant negative correlation between telomere length and frequency of MN, NBUD 
and NPB (Spearman correlation, r = - 0.785, p-value = 0.028) over all study participants 
(Figure 17).  
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Figure 15: Representative images of metaphase spreads following the chromosome-specific telomere length assay.  In 
image (a) are metaphase chromosomes from an individual without dementia; with image (b) showing metaphase chromosomes 
from an individual with dementia. Note the overall decreased fluorescent intensity of the metaphase chromosomes from the 
individual with dementia [most telomeres are not readily visible and less intense than the centromeric control probe] as 
compared to the individual without dementia [all telomeres are easily visualized with bright signals that are comparable in 
intensity to the signal of the centromeric control probe].
(a) 
 
(b) 
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Figure 16: Frequencies of cytome abnormalities (total MN, NBUD and NPB) and 
overall telomere length (signal intensity). Individuals without dementia (n = 5) and 
individuals with dementia (n = 3) are shown. The data is presented as the mean and 
standard deviation for each group. (a) The frequency of cytome aberrations in individuals 
with dementia was significant higher than those observed in individuals without dementia 
(p-value = 0.036, Mann-Whitney U test). (b) Telomere lengths (signal intensities) in 
individuals with dementia were significant higher than those observed in individuals 
without dementia (p-value = 0.036, Mann-Whitney U test). 
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Figure 17: Relationship between frequency of cytome abnormalities and mean 
telomere length (signal intensity). A significant negative correlation between telomere 
signal intensity (length) and the frequency of cytome abnormalities for individuals 
without dementia (white) and individuals with dementia (black) was detected (Spearman 
correlation, r = - 0.785, p-value = 0.028). An individual who was later diagnosed as 
having dementia is also shown (gray). The data are shown as frequencies/intensities in 
trisomic (triangle) and euploid cells (circle). An individual with mosaicism is represented 
by □ with their values being the average of the two cell populations.  
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Chromosomal contents in MN 
The chromatin present in the MN from the trisomic and euploid binucleates was 
determined using SKY (Figures 18 and 19). Of the total of 777 MN scored, the majority 
(85.71%) contained chromatin from a single chromosome. However, the most frequent 
category of MN that was observed contained chromatin from more than one 
chromosome, with these MN accounting for 12.4±3.6% of the total number of MN 
evaluated from individuals without dementia, and 17.7±0.4% in individuals with 
dementia. The frequencies of autosomal and sex chromosome exclusion into micronuclei 
were not significantly different between the dementia groups. However, a non-random 
pattern of chromosomes present in MN was observed for both groups, with chromatin 
from chromosome 16 being present most frequently and chromatin from chromosome 17 
being present least frequently. A Mann-Whitney U test with Bonferroni correction for 
multiple comparisons was applied for these tests [the p-value was set at < 0.002 (i.e., 
0.05/24)]. The chromosome-specific statistical comparisons between the MN from 
individuals with and without dementia are summarized in Table 12. 
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Figure 18: Representative images of a binucleated cell and micronucleus following the CBMN and SKY assays. (a) A 
reverse DAPI image; (b) spectral image; and (c) classified images. In this cell the chromatin content of the micronucleus 
originated from a Y chromosome. 
 
 
(a) 
 
(b) (c) 
Chromosome Y 
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Figure 19: Frequency of chromatin contents in MN observed from individuals based on their dementia status. The 
proportion of MN containing each of the chromosomes is shown for individuals without dementia (dark gray) and individuals 
with dementia (light gray), pooled over all cell types. The data are shown as the mean (histogram) and standard deviation 
(error bar). The frequencies of MN that contain chromatin from more than one chromosome are shown in the “mix” category.  
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Chromosome-specific telomere length profiles 
Chromosome-specific (averaged over the short arm and long arm) telomere 
lengths (probe signal intensities) were also determined for the study participants with and 
without dementia (Figure 20). Individuals with dementia tended to have shorter telomeres 
than the people without dementia for all chromosomes studied. A Mann-Whitney U test 
with Bonferroni correction for multiple comparisons was applied for these tests [the p-
value was set at < 0.002 (i.e., 0.05/24)]. None of the observed difference values reach 
statistical significance. Chromosomes 16 and 17 were found to have the shortest 
telomeres in both the non-demented and dementia group. In this study, chromosome 18 
was found to have the longest telomeres in both groups. Statistical comparisons between 
the individuals from the non-demented and demented groups are summarized in Table 
12. Individuals without dementia appeared to have nearly the same pattern of 
chromosome-specific telomere length (Figure 20b).  
 
We were able to measure chromosome-specific telomere lengths of euploid 
compared to isogenic trisomic cells in the one individual who had two cell populations 
present in their lymphoblast culture (Figure 21). The telomere intensities tended to be 
shorter for nearly all chromosomes in the trisomic cells. However, none of the telomeric 
values were significantly different between the cell types (Figure 21). 
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Figure 20: Chromosome-specific telomere intensity values in individuals without dementia (dark gray) and with 
dementia (light gray). The data are represented by the median (histogram) and interquatile range (error bar). Note that all 
telomeres of individuals with dementia are shorter compared to those without dementia. (b) Trend lines of the mean of the 
telomere intensity values are shown for each chromosome in the individuals without dementia (dark gray) and with dementia. 
Note the nearly parallel course of lines between individuals without dementia (dark gray) and individuals with dementia (light 
gray). 
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Table 12: Summary of statistical analysis for MN content and telomere length
Chromosome 
MN Content Telomere Intensities 
Non-demented Demented 
p-value* 
Non-demented Demented 
p-value* 
Mean 
(Dementia -) 
SD Mean 
(Dementia +) 
SD Mean 
(Dementia -) 
SD Mean 
(Dementia +) 
SD 
1 3.4% 3.8% 1.1% 1.1% 0.55 2.18 0.69 1.56 0.30 0.14 
2 1.7% 1.1% 0.8% 0.7% 0.27 2.30 0.67 1.51 0.24 0.14 
3 2.7% 1.6% 4.4% 3.3% 0.39 2.71 0.58 1.74 0.36 0.04 
4 7.5% 1.8% 7.5% 1.2% 1 2.39 0.47 1.40 0.22 0.04 
5 1.8% 1.7% 2.8% 0.9% 0.52 2.25 0.57 1.59 0.23 0.14 
6 1.3% 0.9% 1.4% 1.2% 0.88 2.43 0.64 1.71 0.27 0.07 
7 0.7% 0.6% 1.9% 1.7% 0.38 2.26 0.54 1.46 0.29 0.04 
8 7.1% 2.9% 7.7% 4.3% 1 2.39 0.61 1.56 0.32 0.07 
9 3.3% 1.7% 4.6% 2.2% 0.39 2.30 0.70 1.63 0.56 0.14 
10 2.1% 1.7% 1.8% 1.7% 1 2.40 0.63 1.69 0.19 0.25 
11 6.1% 1.6% 3.8% 0.8% 0.07 2.21 0.42 1.50 0.19 0.04 
12 6.4% 3.1% 6.3% 3.8% 1 2.18 0.52 1.70 0.15 0.4 
13 7.5% 2.4% 4.5% 1.9% 0.14 2.53 0.36 1.65 0.32 0.04 
14 8.4% 1.1% 7.7% 2.0% 0.79 2.70 0.73 1.63 0.37 0.07 
15 2.1% 2.0% 2.1% 0.9% 1 2.65 0.79 1.59 0.46 0.07 
16 11.4% 3.7% 7.9% 4.1% 0.25 1.96 0.40 1.37 0.23 0.07 
17 0.0% 0.0% 0.7% 0.6% 0.11 2.05 0.56 1.31 0.26 0.07 
18 2.7% 2.1% 2.1% 0.9% 1 2.70 0.70 1.86 0.27 0.14 
19 1.4% 1.0% 1.1% 1.2% 0.63 2.17 0.55 1.40 0.22 0.07 
20 4.6% 1.7% 6.4% 2.2% 0.39 2.40 0.61 1.52 0.32 0.07 
21 2.4% 0.9% 1.5% 0.7% 0.25 2.43 0.75 1.53 0.28 0.07 
22 1.0% 0.7% 1.9% 2.3% 0.88 2.26 0.63 1.62 0.40 0.14 
X 2.1% 3.2% 2.5% 2.3% 0.79 2.56 0.64 1.79 0.33 0.04 
mix 12.4% 3.6% 17.7% 0.4% 0.14  
 
 
  
* p-value prior to Bonferroni 
correction 
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Figure 21: Chromosome-specific telomere intensity profiles in the individual with mosaicism for trisomy 21. 
Chromosome-specific telomere length profiles in euploid and trisomic cells obtained from an individual with mosaicism (but 
not dementia) are shown. (a) The data represent mean (histogram) and standard deviation (error bar) values. (b) The 
comparisons of the mean differences, using a paired t-test, showed no significant differences.
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Discussion 
 
In this study, we originally intended to evaluate the frequency of chromosomal 
instability and chromosomal contents of MN between isogenic trisomic and euploid cells 
obtained from individuals with mosaicism for Down syndrome. Of eight individuals who 
were ascertained for having “mosaicism”, we were only able to obtain both trisomic and 
euploid cells for one of these individuals. Of the 8 cases, 5 lymphoblast cultures had 
nearly all trisomic cells. This change in the proportion of cells could be due to selection 
against the euploid cells that happened either at the time that lymphocytes were 
transformed to lymphoblasts (clonal like selection) at the time of freezing/thawing, or 
during the lymphoblast culture maintenance (differential growth). It is likely that these 
individuals had full trisomy 21 with an “acquired” loss of chromosome 21 that occurred 
later in their lives. It has been reported previously that acquired loss of chromosome 21 
happens in elderly people with Down syndrome (Percy et al., 1993; Jenkins et al., 1997). 
For those 2 individuals who had euploid cells that predominated, they are likely to have 
had “constitutional” mosaicism for Down syndrome, with loss of the trisomic line due to 
cell culture selection as described above.  
 
Considering the parallel between the increase in MN frequency and Alzheimer 
type of dementia (Migliore et al., 2011), one could hypothesize that the increase in MN 
frequency could be related to the early development of Alzheimer symptoms in people 
having Down syndrome. In this study, we observed significantly higher frequencies of 
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chromosomal instability in individuals who had dementia, compared to those without 
dementia, which supports the findings of Migliore and colleagues (2011). We also 
observed that individuals who had dementia had significantly shorter telomere than those 
without dementia, which is in agreement with the previous report by Jenkins and 
colleagues (2008) who looked at mean telomere lengths, but not chromosome-specific 
telomere lengths. Given that free radicals have been purported to play a role in the 
shortening of telomeres (Von Zglinicki, 2000) and that the superoxide dismutase-1 (SOD-
1) gene is located on chromosome 21, which encodes an enzyme that is responsible for 
destroying free radicals, the observation of telomere shortening associated with a trisomic 
complement is a bit counter-intuitive. Increased expression of SOD-1 has been 
documented in individuals with Down syndrome. However, H2O2, a product of the 
catalytic reaction by SOD-1, will break down to a hydroxyl radical (OH
-
). OH
–
 is highly 
toxic, which can result in profound cellular damage (reviewed in Capone, 2001). 
Therefore, individuals with Down syndrome are believed to be vulnerable to oxidative 
damage to DNA, including telomeres. The imbalance between oxygen free radical 
production and scavenging leads to cellular dysfunction, which in turn, has been 
postulated to result in elevated genomic instability (Mancuso et al., 2006). In addition, it 
has been reported that individuals with Down syndrome have an accelerated decline in 
DNA repair capacity with age (Raji and Rao, 1998). This could also contribute to 
chromosomal and/or genomic instability in elderly individuals with Down syndrome.  
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In addition to observing generalized trend toward shortened telomeres in the older 
group having dementia, we observed that chromosome 16 had the shortest telomeres for 
both the demented, as well as the non-demented individuals. While the telomere intensity 
values were not significantly different between the two groups, it is of interest to note 
whether there might be genes localized near the heterochromatic telomere whose activity 
could be altered by telomeric attrition. Two such genes were identified to be of interest. 
One of these genes, called partner and localizer for BRCA2 (PALB2), located on 
chromosome band 16p12.2 and encodes a protein that stabilizes and anchors the BRCA2 
protein to structures within the nucleus. Therefore, PALB2 is essential for allowing the 
DNA double-strand break repair functions of BRCA2, which, in turn, prevents cells from 
accumulating genetic damage that can trigger genomic/chromosomal instability 
(http://omim.org/entry/6103555). Given that MN could be formed as a result of 
misrepaired and unrepaired DNA double strand breaks, shortening of the telomere on 
chromosome 16 could be a factor contributing to the higher frequency of MN observed in 
individuals with Down syndrome when compared to age-matched controls having a 
normal complement, the latter of which is a finding reported by Ferreira, et al. (2009). 
The CREB binding protein (CREBBP or CBP) gene is another gene that is located on 
chromosome 16 (band 16p13.3). The CREBBP gene has been shown to have an essential 
role in long term memory formation in mice (Bourtchouladze et al., 2003) 
(http://omim.org/entry/600140). Given that shortening of the heterochromatic telomeric 
region could alter the chromatin conformation of the distal long arm, thereby potentially 
 122 
 
altering the function of CREBBP gene, this is an interesting gene to consider for future 
studies of the progression of dementia in individuals with Down syndrome.  
 
In this study, we found a significant correlation between telomere shortening and 
increased frequency of MN, NBUD and NPB. It is thought that excessive telomere 
shortening can eventually result in telomere to telomere end fusions and the formation of 
dicentric chromosomes via inappropriate assembly of the telomeric protein structures. 
Using the CBMN and FISH assays, we found that hyperdiploidy, hypodiploidy and NDJ 
were more common alterations than “corrective” changes leading to MN formation for 
chromosome 21 and 13. From MN content analysis using SKY, we found that MN 
containing more than one chromosome (mix) was seen more frequently than MN 
containing a single chromosome. Taken together, one could speculate that telomeric 
shortening is leading to an increased frequency of dicentric chromosome formation in 
older individuals with Down syndrome and that the dicentric chromosomes may 
contribute to the observed increased frequency of chromosomal instability as shown in 
Figure 22. 
 
While we found that the overall telomere lengths (inferred from the reduced 
intensity of signal for the telomeres) of individuals with dementia were significant shorter 
than individuals without dementia, we observed that the telomeres tended to be shorter 
across all chromosomes and the patterns of chromosome-specific telomere length were 
very similar for both groups. However, further studies of more individuals, including 
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individuals with non-mosaic and mosaic Down syndrome, are needed, which ultimately 
may help to identify genomic regions of interest and serve to inform investigators of 
potential candidate genes for future investigations in the etiology of dementia. 
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Figure 22: Diagram showing link between telomere shortening and chromosomal 
instability. Chromosome 21 is shown in red and chromosome 13 is shown in green. The 
left side of the diagram shows the replicated chromosomes’ alignment during metaphase. 
Dicentric chromosomes, which form from end-to-end fusion as a result of telomeric 
shortening, are highlighted with an arrow. The middle of the diagram shows the 
chromosomes following the separation of the sister chromatids during anaphase. As the 
chromosomes are pulled toward the spindle poles, the tension exerted by spindle fibers 
can cause breakage of the dicentric chromosome, which could result in (a) 
nondisjunction; or (b) MN formation following anaphase lagging. The right side of the 
diagram shows patterns that would result from these abnormal segregation events in cells 
evaluated after the CBMN and FISH assays. Note the content of the MN in (b) is 
comprised of a combination of chromatin from chromosomes 21 and 13 (mix). 
 
 
(a) 
Trisomic binucleate 
with nondisjunction 
of chromosome 21 
(b) 
Trisomic binucleate 
with MN containing 
chromosome 21 and 13 
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Chapter 5 
Summary, conclusions, and future directions 
 
A. Array-based technology for mosaicism detection. 
- It is important that geneticists who are interpreting the results of microarray studies gain 
experience in the assessment of cases having mosaicism. Using the default software 
analysis setting for copy number calling alone, is not sufficient to recognize individuals 
with mosaicism involving a minor cell population that is present in less than 30%  of cells 
since the software routinely categorizes log2 ratio changes from 0-30% as copy number 
neutral findings. By expanding our analysis to include an assessment of the smooth signal 
of the log2 ratio, cases having a minor cell population in as few as 15-20% of cells could 
be detected. However, FISH remains the “gold standard” for mosaicism detection. In 
addition, FISH should be considered for confirmation when low level mosaicism is 
suspected and/or to confirm/refute equivocal array-based results. 
 
- Array-based technology has limitations in identifying mosaicism, and is unable to detect 
unbalanced structural chromosome rearrangements, and ploidy changes; however, it 
shows strengths in its ability to identify previously unrecognized chromosomal 
abnormalities. In addition, due to its high resolution compared to the standard G-banding 
analysis, array-based technology allows for refinement of breakpoinst of unbalanced 
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structural chromosome abnormalities. Using the SNP array, the origin of a segregation 
error (meiosis or mitosis, when coupled with an assessment of parental patterns), and 
long contiguous stretches of homozygosity (LCSH), the latter of which may be indicative 
of isodisomic uniparental disomy (UPD) or loss of heterozygosity (LOH), can be 
detected. 
 
- The relative fluorescence intensities obtained from microarray data were positively 
correlated with the percentage of trisomic cells determined by the “gold standard” FISH 
methodology. Thus, for specimens in which mosaicism is detected, array-based 
technology appears to yield reliable estimates of the proportion of cell populations 
present 
  
- A further study including more individuals with various levels of mosaicism for trisomy 
21 syndrome, mosaicism involving other constitutional chromosome abnormalities, and 
multiple clonal cell lines from cancer specimens should be evaluated to assess reliability 
and limitations of this assay by laboratories before it is used in a diagnostic setting (i.e., 
the validation should include mosaic cases) .  
 
B. Chromosome-specific telomere length profiles in euploid and trisomic cells from 
younger individuals with mosaicism for trisomy 21. 
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- A weak, non-significant negative correlation between telomere intensity values and the 
percentage of trisomic cells present in the mosaic probands was observed in this study. 
The lack of a clear effect of the proportion of trisomy cells could be attributable to the 
small sample size, or a skewing of the distribution of trisomic cells in the study 
participants toward low levels (less than 20%). Alternatively, the influence of the 
trisomic imbalance could be limited to the cellular boundaries, with the euploid cells 
showing no influence from the trisomic cells.   
 
- A weak, non-significant negative correlation between telomere intensity and age was 
also observed. The lack of an age effect on telomere intensity values in this young study 
cohort of individuals having mosaicism (majority of participants were less than 5 years 
old) is consistent with expectations from studies of young individuals having euploid 
(normal) chromosomal complements. 
 
- Both trisomic and euploid cells had strikingly similar chromosome-specific telomere 
length profiles, which imply that the trisomy 21 imbalance has a minimal impact on 
telomere lengths in this young population, with any influences that were present tending 
to be generalized for all chromosomes. Although no clear generalized effect of trisomy 
21 was observed in this young study cohort, case by case differences in overall telomere 
intensity between euploid and trisomic cell “within a person” were detected for a subset 
of individuals. 
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- Telomere lengths were not equally distributed among all chromosome arms, with a 
common pattern of telomere length being observed between genetically unrelated 
individuals. In addition, the chromosome-specific telomere length profiles in this cohort 
tended to parallel the profiles that have been reported in normal populations.  
 
- Further studies should be carried out in extended populations with individuals from 
older ages. In addition, a longitudinal study in this young cohort may provide information 
regarding a potential differential rate of telomere shortening in trisomic compared to 
euploid cells. 
 
C. Frequency of chromosomal instability and chromosome-specific telomere length 
profiles in older individuals with Down syndrome with and without dementia. 
 
- Significantly higher frequencies of cytome abnormalities and significantly shorter 
telomere lengths were observed in individuals with Down syndrome who had dementia, 
compared to those without dementia. In addition, a significant correlation between 
telomere shortening and an increased frequency of cytome abnormailties was observed. 
Other cellular alterations, such as hyperdiploidy, hypodiploidy, and nondisjuction 
(imbalances) were more common than “corrective” changes leading to micronuclei (MN) 
formation. Using SKY, MN containing more than one chromosome were noted to arise 
more often than MN containing a single chromosome. Taken together, these findings 
suggest that telomere shortening may lead to an increased frequency of dicentric 
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chromosome formation and that the dicentric interchromosomal abnormalities may be an 
intermediate between the observed increased frequency of hyperdiploidy, hypodiploidy, 
NDJ, and MN containing more than one chromosome. 
 
- Further studies, especially the CBMN in combination of FISH and SKY, should be 
carried out in an extended population of older individuals having mosaicism for trisomy 
21 with and without dementia to further clarify the impact of the trisomic imbalance on 
the acquisition dementia. In addition, investigations in young and older individuals with 
mosaicism for Down syndrome may provide insight about the effects of constitutional 
aneuploidy on the frequency of age-related, acquired chromosomal instability. 
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